



US008592569B2

(12) **United States Patent**  
**Inoue et al.**

(10) **Patent No.:** **US 8,592,569 B2**  
(45) **Date of Patent:** **Nov. 26, 2013**

(54) **SMALL RNA-DEPENDENT TRANSLATIONAL REGULATORY SYSTEM IN CELL OR ARTIFICIAL CELL MODEL**

(75) Inventors: **Tan Inoue**, Kyoto (JP); **Hirohide Saito**, Kyoto (JP); **Yusho Kato**, Hyogo (JP); **Kenichi Yoshikawa**, Kyoto (JP); **Ayako Yamada**, Paris (FR); **Toru Yamanaka**, Hyogo (JP)

(73) Assignee: **Japan Science and Technology Agency**, Saitama (JP)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 92 days.

(21) Appl. No.: **12/743,908**

(22) PCT Filed: **Nov. 21, 2008**

(86) PCT No.: **PCT/JP2008/071214**

§ 371 (c)(1),  
(2), (4) Date: **Aug. 31, 2010**

(87) PCT Pub. No.: **WO2009/066758**

PCT Pub. Date: **May 28, 2009**

(65) **Prior Publication Data**

US 2010/0323356 A1 Dec. 23, 2010

(30) **Foreign Application Priority Data**

Nov. 22, 2007 (JP) ..... 2007-303661

(51) **Int. Cl.**  
**C07H 21/04** (2006.01)

(52) **U.S. Cl.**  
USPC ..... **536/24.5**

(58) **Field of Classification Search**  
USPC ..... 536/24.5  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

6,428,971 B1 \* 8/2002 Shinabarger et al. .... 435/15  
2002/0169306 A1 \* 11/2002 Kitazato et al. .... 536/23.4  
2006/0063232 A1 \* 3/2006 Grabherr et al. .... 435/69.1  
2007/0136827 A1 \* 6/2007 Collins et al. .... 800/14

**FOREIGN PATENT DOCUMENTS**

JP 2005-341865 12/2005

**OTHER PUBLICATIONS**

MHS2007 & Micro-Nano COE Final Conference Program, 2007 International Symposium on Micro-NanoMechatronics and Human Science, Nov. 11-14, 2007, Nagoya, Japan, pp. 1-16.\*  
Bauer et al., "Engineered riboswitches as novel tools in molecular biology," *J. Biotechnol.* 124(1):4-11 (2006).  
Davidson et al., "Synthetic RNA circuits," *Nature Chem. Biology* 3(1):23-8 (2007).

Isaacs et al., "Engineered riboregulators enable post-transcriptional control of gene expression," *Nature Biotechnol.* 22(7):841-7 (2004).  
Repoila et al., "Small non-coding RNAs, co-ordinators of adaptation processes in *Escherichia coli*: the Rpos paradigm," *Mol. Microbiol.* 48(4):855-61 (2003).

Extended European Search Report and Written Opinion mailed on Jan. 24, 2011 in related European Application No. EP08852782.5.

Altuvia, Shoshay, et al., The *Escherichia coli* OxyS regulatory RNA represses fhlA translation by blocking ribosome binding, *The EMBO Journal*, 1998, vol. 17, No. 20, p. 6069-6075.

Chen, Guangnan, et al., Features of a Leader Peptide Coding Region that Regulate Translation Initiation for the Anti-Trap Protein of *B. subtilis*, *Molecular Cell*, 2004, vol. 13, p. 703-711.

Isaacs, Farren J., et al., Engineered riboregulators enable post-transcriptional control of gene expression, *Nature Biotechnology*, Jul. 2004, vol. 22, No. 7, p. 841-847.

Isaacs, Farren, et al., RNA synthetic biology, *Nature Biotechnology*, May 2006, vol. 24, No. 5, p. 545-554.

Ishikawa, Keitaro, et al., Expression of a cascading genetic network within liposomes, *FEBS*, Sep. 2004, p. 387-390.

Kashida, Shunichi, et al., Jinko RNA to RNAi Mochiita Hito Saibo deno Hon'yaku Seigyo System, Dai 9 Kai Nippon RNS Gakkai Nenkai (Dai 9 Kai RNA Meeting) Yoshishu, Jul. 28, 2007, p. 199, P-53.

Noireaux, Vincent, et al., A vesicle bioreactor as a step toward an artificial cell assembly, *Proceedings National Academy Science*, 2004, vol. 101, No. 51, p. 17669-17674.

Nomura, Shin-ichiro, et al., Gene Expression within Cell-Sized Lipid Vesicles, *ChemBioChem*, 2003, 4 (11), p. 1172-1175.

Saito, Hirohide and T. Inoue, et al., RNA and RNP as new molecular parts in synthetic biology, *J. of Biotechnology*, 2007, vol. 132, p. 1-7.

Sharma, Cynthia M., et al. A small RNA regulates multiple ABC transporter mRNAs by targeting C/A-rich elements inside and upstream of ribosome-binding sites, *Gene & Development*, Nov. 2007, vol. 21, p. 2804-2817.

International Search Report mailed Feb. 24, 2009 in related International application No. PCT/JP2008/071214.

(Continued)

*Primary Examiner* — Brian Whiteman

(74) *Attorney, Agent, or Firm* — Meunier Carlin & Curfman, LLC

(57) **ABSTRACT**

An object of the present invention is to construct an mRNA which specifically responds to a short RNA sequence and can activate, repress, and regulate the translation of the desired gene, and to construct an artificial cell model system using a liposome comprising the mRNA and a cell-free translational system encapsulated therein. The present invention provides: an mRNA comprising a target RNA-binding site located immediately 5' to the ribosome-binding site, and a nucleotide sequence located 5' to the target RNA-binding site, the nucleotide sequence being complementary to the ribosome-binding site; an mRNA comprising a small RNA-binding site located 3' to the start codon, and a nucleotide sequence located 3' to the small RNA-binding site, the nucleotide sequence encoding a protein; and a liposome comprising any of these mRNAs encapsulated therein.

(56)

**References Cited**

## OTHER PUBLICATIONS

Saito H, et al. "Towards Constructing Synthetic Cells: RNA/RNP Evolution and Cell-Free Translational Systems in Giant Liposomes," Micro-Nanomechatronics and Human Science, 2007. MHS '07. International Symposium on. Nov. 12, 2007, pp. 286-291.

Baker, CS., et al., CsrA inhibits translation initiation of *Escherichia coli* hfq by binding to a single site overlapping the Shine-Dalgarno sequence, J. Bacteriology, Aug. 2007, vol. 189, No. 15, p. 5472-5481.

Caban, et al., "The L7Ae RNA binding motif is a multifunctional domain required for the ribosome-dependent Sec incorporation activity of Sec insertion sequence binding protein 2," Mol. Cell. Biol. 27(18):6350-60 (2007).

Caillet, et al., "The modular structure of *Escherichia coli* threonyl-tRNA synthetase as both an enzyme and a regulator of gene expression," Mol. Microbiol. 47(4):961-74 (2003).

Edwards, et al., "Riboswitches: small-molecule recognition by gene regulatory RNAs," Curr. Opin. Struct. Biol. 17(3):273-9 (2007).

Ptashne, M., "Regulation of Transcription: from lambda to eukaryotes," Trends in Biochemical Sciences, 30 (6):275-279 (2005).

Winkler et al., "Regulation of bacterial gene expression by riboswitches," Ann. Rev. Microbiol. 59:487-517 (2005).

International Search Report, mailed Dec. 16, 2008 in related International application No. PCT/JP2008/071213.

Hara, Tomoaki, et al., RNP Motif L7Ae/BoxC/D o Riyo shita Tanpakushitsu Oto Hon'Yaku Seigyo System no Kochiku, Dai 10 Kai the RNA Society of Japan Nenkai Yoshishu, Jul. 23, 2008, p. 141 (P-41).

Kobayashi Tetsuhiro, et al., RNP Motif o Riyo shita Tanpakushitsu Oto Hon'yaku Seigyo System no Kochiku, 30th Annual Meeting of the Molecular Biology Society of Japan, Dai 80 Kai The Japanese Biochemical Society Taikai Godo Taikai Koen Yoshishu, Nov. 25, 2007, p. 879 (4P-1323).

\* cited by examiner

FIG.1




FIG.2




FIG.3(A)

5'-U<sup>A</sup>G<sup>A</sup>GAGAAGCAGGGCACGUGCA-3'

FIG.3(B)




FIG.4




FIG.5




FIG.6




FIG.7




FIG.8




FIG.9




FIG.10(A)

FIG.10(B)




FIG.11(A)

FIG.11(B)




FIG.12




FIG.13




FIG.14(A) FIG.14(B)




FIG.15




FIG.16




FIG.17(A)




FIG.17(B)




FIG.17(C)




FIG.18(A)




FIG.18(B)




FIG.19




FIG.20




FIG.21




FIG.22




FIG.23




FIG.24




FIG.25




FIG.26




FIG.27




FIG.28




FIG.29




FIG.30




FIG.31




FIG.32




FIG.33




FIG.34




FIG.35




FIG.36




FIG.37




FIG.38




FIG.39





FIG.40



**SMALL RNA-DEPENDENT TRANSLATIONAL  
REGULATORY SYSTEM IN CELL OR  
ARTIFICIAL CELL MODEL**

TECHNICAL FIELD

The present invention relates to a translational regulatory system in a cell or an artificial cell model.

BACKGROUND ART

With the progress of RNA structural biology, it has been increasing evident in recent years that in vivo complicated RNA molecules are composed of accumulated RNA modules, which can be divided physically into functional units. The effectiveness of modular engineering has already been demonstrated in such a way that: an artificial functional RNA molecule has been constructed by a method which involves combining a plurality of naturally occurring RNA modules; and further, an artificial ribozyme has been developed successfully using the in vitro selection method.

On the other hand, there are naturally occurring riboswitches which have metabolite (e.g., amino acids or nucleic acids)-binding RNA modules on mRNAs and regulate gene expression in a metabolite concentration-dependent manner. Specifically, riboswitches are known, such as adenine riboswitches, glycine riboswitches, and SAM riboswitches. It has been revealed that these riboswitches regulate the interaction between the SD sequence/start codon and the ribosome associated with ligand binding-induced structural change in mRNA or regulate terminator structures.

Moreover, it has been increasing evident in recent years that small RNA molecules such as micro-RNAs play an important role in the development, differentiation, canceration, etc., of cells. The expression of these small RNA molecules dynamically varies depending on cell states or intracellular localization. Thus, it has been expected to develop a technique of detecting the expression of these small RNA molecules and detecting cells according to the expression levels, or a technique of regulating the fate of cells according to the expression levels.

Heretofore, a biosensor is known, which uses a nucleic acid probe for detecting a target nucleic acid, wherein the nucleic acid probe uses HIV DNA as a substrate and is structurally changed upon hybridization to the target nucleic acid to form an intracellular hybridization site and a stem moiety containing a self nucleic acid enzyme (see Patent Document 1). This technique is aimed at developing a biosensor and is not aimed at constructing an artificial information conversion system which converts an arbitrary input factor (e.g., miRNA) to an arbitrary output (e.g., GFP). Furthermore, in this technique, the effect of responsiveness to RNA substrates such as miRNAs is unknown, because the substrate used is DNA.

A technique of regulating translation reaction within *E. coli* using an artificial RNA is also known (see Non-Patent Document 1). However, this technique is a system intracellularly constructed in advance. Therefore, the possibility cannot be denied that other factors participate in the translational regulation. Moreover, the optimal concentrations of a substrate RNA and the artificial RNA cannot be adjusted strictly.

A technique of encapsulating a DNA or mRNA together with a cell-free translational system into liposomes prepared by natural swelling is known (see Non-Patent Documents 2 and 3). However, of all the liposome prepared by natural swelling, only approximately 10% actually promoted translation reaction, and it was difficult to promote translation reaction within all the liposomes.

On the other hand, it has been reported recently that a cell-free translational system is expressed within liposomes prepared from an emulsion, which is a micrometer-scale cell-sized droplet (see Non-Patent Document 4). However, this method requires the procedure of collecting the liposomes by centrifugation and therefore hardly performs the simultaneous real-time monitoring of translation within a plurality of liposomes. Moreover, the conventional technique used a translational system based on cell extracts and therefore, could not exclude the influence of unknown factors.

Furthermore, intraliposomal translational regulation has not been developed so far.

Patent Document 1: Japanese Patent Publication No. 2005-341865

Non-Patent Document 1: Isaacs F J et al; Nat Biotechnol., 22 (7): 841-7, 2004

Non-Patent Document 2: Ishikawa K et al; FEBS Lett., 576 (3): 387-90, 2004

Non-Patent Document 3: Nomura S M et al; Chembiochem., 4 (11): 1172-5, 2003 Gene expression within cell-sized lipid vesicles

Non-Patent Document 4: Vincent Noireaux et al; Proc Natl Acad Sci USA., 101 (51): 17669-74, 2004

DISCLOSURE OF THE INVENTION

Problems to be Solved by the Invention

An object of the present invention is: to construct an mRNA which responds to the desired molecule and can activate the translation of the desired gene; to construct an artificial information conversion system which converts arbitrary input information to the output of a target protein; and to construct a translational regulatory system in a cell or in an artificial cell model using a cell-free translational system.

Means for Solving the Problems

The present invention has been achieved for attaining the object. Specifically, according to one embodiment, the present invention provides an mRNA comprising a small RNA-binding site located 5' to the ribosome-binding site and a nucleotide sequence located 5' to the small RNA-binding site, the nucleotide sequence being complementary to the ribosome-binding site. This mRNA is also referred to as an ON switch mRNA.

According to another embodiment, the present invention provides a method for translational regulation of mRNA, comprising mixing the mRNA with a small RNA complementarily binding to the small RNA-binding site in the mRNA.

According to a further embodiment, the present invention provides a translation/expression regulation system comprising the mRNA.

According to a further embodiment, the present invention provides an mRNA comprising a small RNA-binding site located 3' to the start codon and a nucleotide sequence located 3' to the small RNA-binding site, the nucleotide sequence encoding a protein. This mRNA is also referred to as an OFF switch mRNA.

According to a further embodiment, the present invention provides a method for translational regulation of mRNA, comprising mixing the mRNA with a small RNA complementarily binding to the small RNA-binding site, and a translation/expression regulation system comprising the mRNA.

According to a further embodiment, the present invention provides a translation/expression regulation system comprising

ing the ON switch mRNA and the OFF switch mRNA, wherein the small RNA-binding sites in the ON switch mRNA and in the OFF switch mRNA have identical nucleotide sequences.

According to a further embodiment, the present invention provides an mRNA comprising: a small RNA-binding site located 5' to the ribosome-binding site; a nucleotide sequence located 5' to the small RNA-binding site, the nucleotide sequence being complementary to the ribosome-binding site; a nucleotide sequence located 5' to the nucleotide sequence complementary to the ribosome-binding site, the nucleotide sequence being identical to the small RNA-binding site; a sequence located 3' to the start codon, the sequence being identical to at least 6 consecutive bases of a small RNA; and a nucleotide sequence located 3' to the sequence identical to at least 6 consecutive bases of a small RNA, the nucleotide sequence encoding a protein. This mRNA is also referred to as a double ON switch mRNA.

According to a further embodiment, the present invention provides an artificial information conversion method comprising the steps of: detecting a small RNA expression level using the ON switch mRNA; and activating the translation of a target protein. According to a further embodiment, the present invention provides an artificial information conversion method comprising the steps of: detecting a small RNA expression level using the OFF switch mRNA; and repressing the translation of a target protein. These artificial information conversion methods further comprise the step of using a combination of the ON switch mRNA and the OFF switch mRNA specifically reacting with identical small RNAs, to simultaneously perform the activation of the translation of the protein encoded by the ON switch mRNA and the repression of the translation of the protein encoded by the OFF switch mRNA.

According to a further embodiment, the present invention provides a liposome comprising any of these mRNAs encapsulated therein.

According to a further embodiment, the present invention provides a liposome comprising an mRNA or DNA and a cell-free translational system encapsulated therein.

The liposome can be obtained by a production method comprising the steps of: mixing one or more phospholipids, the mRNA or DNA, the cell-free translational system, and an aqueous solution into an oily liquid to form a W/O emulsion in which the mRNA or DNA and the cell-free translational system are encapsulated in the phospholipid vesicle; adding an oily liquid containing outer membrane lipids dissolved therein, to an aqueous phase to form a molecular membrane in which the lipids are arranged at the oil/water interface; and adding the W/O emulsion to the oil phase side of the interface and moving the W/O emulsion to the aqueous phase side of the interface such that the outer membrane lipid is added outside of the W/O emulsion to form a liposome.

According to a further embodiment, the present invention provides a method for real-time monitoring of intraliposomal protein translation reaction, comprising the step of microscopically observing the liposome after the liposome formation step.

#### Advantage of the Invention

The present invention has the advantage that an mRNA according to the present invention can perform translational regulation of a desired gene in response to the presence of a small RNA.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram showing an mRNA according to the first embodiment in a switch OFF state;

FIG. 2 is a diagram showing the mRNA according to the first embodiment in a switch ON state;

FIG. 3A is a schematic diagram showing miRNA164 (SEQ ID NO:29), and FIG. 3B is a schematic diagram showing the secondary structure of 5' miR164-responsive EGFP mRNA (SEQ ID NO:49);

FIG. 4 is a graph showing assay on 5' miR164-responsive EGFP;

FIG. 5 is a graph showing assay on 5' miR164-responsive DsRed Monomer;

FIG. 6 is a graph showing assay on 5' miR171-responsive EGFP;

FIG. 7 is a graph showing assay on 5' miR170-responsive EGFP;

FIG. 8 is a schematic diagram showing the formation of a liposome in a PDMS chamber;

FIG. 9 is a diagram schematically showing the formation of a liposome;

FIG. 10A is a photograph showing fluorescence (fluorescent is absent) within DNA-unencapsulated liposomes, and FIG. 10B is a phase-contrast microscopic photograph showing that the liposomes are stably present, wherein the DNA-unencapsulated liposomes were left standing for 1 hour in advance;

FIG. 11(A) is a photograph showing fluorescence within liposomes in which an EGFP-encoding DNA was encapsulated, and FIG. 11B is a phase-contrast microscopic photograph showing that the liposomes are present, wherein the DNA-encapsulated liposomes were confirmed 1 hour after the encapsulation to have intraliposomal EGFP expression;

FIG. 12 is a microscopic photograph after liposome formation using 3 kinds of Feeding solutions, a 0.5 mM egg PC solution, and 2 kinds of Liposome inside solutions and subsequent incubation at 37.degree. C. for 60 minutes;

FIG. 13 is a microscopic photograph showing the fluorescence of a liposome comprising an EGFP-encoding DNA and a cell-free translational system encapsulated therein, upon activation (0 min) and subsequently at 15-minute intervals (i.e., 15 min, 30 min, 45 min, 60 min, and 135 min after the activation);

FIG. 14A is a microscopic photograph showing the fluorescence of a liposome upon activation of an RNA-responsive artificial RNA switch (0 min), FIG. 14B is a microscopic photograph showing the fluorescence of the liposome 60 min after the activation;

FIG. 15 is a diagram showing an mRNA according to the third embodiment in a switch ON state;

FIG. 16 is a diagram showing the mRNA according to the third embodiment in a switch OFF state;

FIG. 17A shows an ON switch mRNA according to the fourth embodiment in a switch OFF state, FIG. 17B shows an OFF switch mRNA according to the fourth embodiment in a switch ON state, and FIG. 17C shows a small RNA specifically binding to both the mRNAs of FIGS. 17A and 17B;

FIG. 18A shows the state where the small RNA of FIG. 17C is added to the ON switch mRNA of FIG. 17A, and FIG. 18B shows the state where the small RNA of FIG. 17C is added to the OFF switch mRNA of FIG. 17B;

FIG. 19 shows a double ON switch mRNA according to the fifth embodiment in a switch OFF state;

FIG. 20 shows the double ON switch mRNA according to the fifth embodiment in a switch ON state;

FIG. 21 is a graph showing assay on a 5' miR164-responsive EGFP switch;

FIG. 22 is a graph showing assay on a 5' miR156-responsive EGFP switch;

5

FIG. 23 is a graph showing assay on a 5' miR164-responsive DsRed Monomer switch;

FIG. 24 is a graph showing assay on a 5' miR156-responsive DsRed Monomer switch;

FIG. 25 is a graph showing assay on 5' miR164-responsive DsRed Monomer and 5' miR156-responsive EGFP;

FIG. 26 is a diagram showing miR156 (SEQ ID NO:35), anti miR156 (SEQ ID NO:37), and an miR156-responsive EGFP OFF switch (SEQ ID NO:50; SEQ ID NO:51);

FIG. 27 is a diagram showing miR164 (SEQ ID NO:29), anti miR164 (SEQ ID NO:39), and an miR164-responsive EGFP OFF switch (SEQ ID NO:52; SEQ ID NO:53);

FIG. 28 is a graph showing assay on an miR156-responsive EGFP OFF switch;

FIG. 29 is a graph showing assay on an miR164-responsive EGFP OFF switch;

FIG. 30 is a diagram showing miR156 (SEQ ID NO:35), anti miR156 (SEQ ID NO:37), and an miR156-responsive DsRed Monomer OFF switch (SEQ ID NO:54; SEQ ID NO: 51);

FIG. 31 is a diagram showing miR164 (SEQ ID NO:29), anti miR164 (SEQ ID NO:37), and an miR164-responsive DsRed Monomer OFF switch (SEQ ID NO:55; SEQ ID NO: 53);

FIG. 32 is a graph showing assay on an miR156-responsive DsRed Monomer OFF switch;

FIG. 33 is a graph showing assay on an miR164-responsive DsRed Monomer OFF switch;

FIG. 34 is a graph showing assay on an miR164-responsive EGFP OFF switch and an miR164-responsive DsRed Monomer ON switch;

FIG. 35 is a graph showing assay on a 5' miR156-responsive EGFP ON switch and an miR156-responsive DsRed Monomer OFF switch supplemented with each concentration of miR156 or miR164;

FIG. 36 is a graph showing assay on a 5' miR164-responsive EGFP ON switch and an miR164-responsive DsRed Monomer OFF switch supplemented with each concentration of miR164 or miR156;

FIG. 37 is a diagram showing miRNA159a (SEQ ID NO:44), RCmiRNA159a (SEQ ID NO:45), and the secondary structure of an miRNA159a-responsive EGFP ON switch as a double ON switch mRNA (SEQ ID NO: 56; SEQ ID NO:57);

FIG. 38 is a diagram showing miRNA163 (SEQ ID NO:28), RCmiRNA163 (SEQ ID NO:47), and the secondary structure of an miRNA163-responsive EGFP ON switch as a double ON switch mRNA (SEQ ID NO:58, SEQ ID NO:59);

FIG. 39 is a graph showing assay on an miRNA159a-responsive EGFP ON switch; and

FIG. 40 is a graph showing assay on an miRNA163-responsive EGFP ON switch.

#### DESCRIPTION OF SYMBOLS

- 1 mRNA
- 2 ribosome-binding site
- 3 small RNA-binding site
- 4 open reading frame
- 4a start codon AUG
- 4b nucleotide sequence encoding a gene of a protein to be expressed
- 5 nucleotide sequence complementary to the ribosome-binding site
- 6 small RNA
- 7 ribosome

6

8 sequence complementarily binding to a portion of the small RNA-binding site

10 PDMS chamber

11 egg PC

12 egg PC

13 Feeding Solution

14 emulsion

15 Liposome Inside Solution

16 liposome

10 20 ribosome-binding site

30 sequence complementary to a small RNA

40 nucleotide sequence encoding DsRed

41 open reading frame

41a start codon AUG

15 41b nucleotide sequence 41b encoding EGFP

50 sequence complementary to the ribosome-binding site

60 small RNA

#### BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention will be described in detail with reference to the embodiments. However, the description below is not intended to limit the present invention.

An mRNA according to the first embodiment of the present invention is characterized by comprising a small RNA-binding site located 5' to the ribosome-binding site and a sequence located 5' to the small RNA-binding site, the sequence being complementary to the ribosome-binding site. An mRNA 1 shown in FIG. 1 comprises a ribosome-binding site 2, a small RNA-binding site 3, an open reading frame 4, and a sequence 5 complementary to the ribosome-binding site. [mRNA]

The mRNA 1 according to this embodiment may be an arbitrary mRNA that has the ribosome-binding site 2 and has translational functions. The sequence of the open reading frame 4 is not limited to a particular sequence. Moreover, the mRNA 1 may be an mRNA having a 5'-terminal stem-loop structure (not shown) for enhancing its transcriptional efficiency. Examples of the 5'-terminal stem-loop structure include, but not limited to, usually known structures. Those skilled in the art can introduce an arbitrary stem-loop structure for enhancing transcriptional efficiency into the 5' end according to the standard method.

The sequence of the open reading frame 4 may have a gene that can be expressed into the desired protein, and has a start codon, though it is not limited to a particular sequence. For example, an mRNA having an open reading frame 4 having a gene encoding a fluorescent protein can be used for the purpose of confirming whether the translational functions act. Examples of the fluorescent protein include EGFP, GFP-UV, and DsRed. Their sequences are generally known.

In addition, the sequence of the open reading frame 4 may encode a protein that works as a particular pharmaceutical agent. Specifically, examples of the protein include, but not limited to, apoptosis-inducing proteins Bim and Bax, apoptosis-promoting BH3 peptides, and variants thereof [Small RNA-Binding Site]

The small RNA-binding site 3 has a sequence complementary to a particular small RNA. The small RNA is a generic name for RNAs that have a base length of 10 bases to 80 bases and have the property of regulating cell functions through their interactions with RNAs or proteins. In this embodiment, a small RNA of any sequence and any base length can be used. Preferably, the small RNA itself does not form a stem structure at a temperature around 37° C.

One example of the small RNA includes an miRNA. The miRNA is an abbreviation of micro-RNA. The miRNA, which is a small, protein-noncoding RNA molecule, is thought to participate in various life phenomena such as development, differentiation, and proliferation. Approximately several hundreds of kinds of specific miRNA sequences have been identified in organisms such as *Arabidopsis*, humans, and mice, and these sequences are already known in databases such as miRbase.

More specifically, in this embodiment, *Arabidopsis*-derived miRNAs miR164, miR170, and miR171 can be used, though the miRNA is not limited thereto.

The small RNA-binding site **3** according to this embodiment can be set to a sequence complementary to a particular small RNA. Alternatively, the small RNA-binding site **3** may be complementary to not only the full nucleotide sequence of the small RNA but also at least 15 bases or more, preferably 20 bases or more, of the small RNA. Moreover, this complementary sequence may have 1 to 3 mutations in some cases. Examples of the cases particularly include the cases in which strong hydrogen bond can be formed when the site forming the complementary sequence is rich in GC.

The small RNA-binding site **3** is located 5' to the ribosome-binding site **2**. In this embodiment, the term "5' to the ribosome-binding site **2**" in the mRNA **1** refers to a position 1 to 15 bases (inclusive) distant from the ribosome-binding site **2**, preferably a position 1 to 10 bases (inclusive) distant from the ribosome-binding site **2**, more preferably 1 to 5 bases (inclusive) distant from the ribosome-binding site **2**, toward the 5' end. This range can be determined within a range that can achieve the activation of translation reaction in response to a targeted substrate small RNA. In FIG. 1, a line is described between the small RNA-binding site **3** and the ribosome-binding site **2**. However, the small RNA-binding site **3** and the ribosome-binding site **2** are not necessarily required to be adjacent to each other. In this embodiment, a nucleotide sequence that may be located between the small RNA-binding site **3** and the ribosome-binding site **2** is not limited to a particular nucleotide sequence.

[Sequence Complementary to Ribosome-Binding Site]

The sequence **5** complementary to the ribosome-binding site is located 5' to the small RNA-binding site **3** in the mRNA **1**. The sequence **5** complementary to the ribosome-binding site is intended to complementarily bind to the ribosome-binding site **2** placed on the same mRNA **1** to form a stem structure. Thus, the sequence **5** complementary to the ribosome-binding site can specifically have UCUCU from the 5' end. In this context, the ribosome-binding site is not limited to AGGAGA and is known to be an AG-rich sequence. Therefore, the sequence **5** is not limited thereto as long as the sequence is complementary to the ribosome-binding site. In this context, the sequence **5** complementary to the ribosome-binding site may further have a sequence complementary to approximately 1 to 10 bases located immediately 3' to the ribosome-binding site **2** and/or approximately 1 to 10 bases located immediately 5' thereto.

The sequence **5** complementary to the ribosome-binding site may be located immediately 5' to the small RNA-binding site **3** or may be placed via 1 to 10 bases, preferably 1 to 5 bases, downstream thereof. In FIG. 1, a line is described between the small RNA-binding site **3** and the sequence **5** complementary to the ribosome-binding site. However, the small RNA-binding site **3** and the sequence **5** complementary to the ribosome-binding site are not necessarily required to be adjacent to each other. In this embodiment, a nucleotide sequence that may be located between the small RNA-bind-

ing site **3** and the sequence **5** complementary to the ribosome-binding site is not limited to a particular nucleotide sequence. [Action as RNA Switch]

The mRNA **1** having the characteristics as described above can act as an artificial RNA switch. Specifically, it can act to initiate translation in response to the presence of a particular small RNA. This action will be described with reference to the drawings. The mRNA **1** according to this embodiment assumes a structure shown in FIG. 1 (switch OFF state), in the absence of the particular small RNA, in a Hepes buffer at 25 to 42° C., preferably approximately 33 to 41° C. and pH of approximately 6.0 to 8.5, preferably approximately 6.5 to 8.0. Specifically, the ribosome-binding site **2** forms a complementary strand with the sequence **5** (located 5' to the ribosome-binding site) complementary to the ribosome-binding site to form a stem structure. Therefore, a ribosome, if any, cannot bind to the ribosome-binding site **2**. Thus, the translation of the mRNA **1** does not occur. Further, in this state, the small RNA-binding site **3** forms a loop structure as shown in the diagram.

Next, a small RNA **6** is added in 0.25 to 20-fold amount (mol) with respect to the mRNA, to the mRNA assuming the structure shown in FIG. 1 in a Hepes buffer at 25 to 42° C., preferably around 33 to 41° C. and pH of approximately 6.0 to 8.5, preferably approximately 6.5 to 8.0. This small RNA **6** has a sequence complementary to the small RNA-binding site **3**. The state in the presence of the miRNA **6** is shown in FIG. 2. In FIG. 2, the small RNA **6** complementarily binds to the small RNA-binding site **3**. This binding deforms the stem structure of the ribosome-binding site **2**, which is in turn placed in a state capable of binding to a ribosome **7**. Thus, the ribosome **7**, if any, initiates the translation of the mRNA **1** (switch ON) to form the particular protein.

Furthermore, translational regulation dependent on the amount of the small RNA added can be achieved by changing the amount of the small RNA added with respect to the amount of the mRNA. Moreover, translation can be switched OFF again by adding small RNA antisense thereto.

In light of the action, even a method for translational regulation of mRNA can be provided using the mRNA according to the first embodiment. This method comprises mixing the mRNA with a small RNA complementarily binding to the small RNA-binding site. Moreover, a method for translational regulation of mRNA can also be provided, which comprises mixing the mRNA with a small RNA complementarily binding to the small RNA-binding site. Furthermore, a translation/expression regulation system comprising the mRNA can also be provided. In this case, preferably, the system contains even a small RNA. Furthermore, an artificial information conversion method can also be provided, which comprises the steps of: detecting a small RNA expression level using the mRNA; and activating the translation of a target protein. In the artificial information conversion method, owing to the properties of the mRNA according to the first embodiment, the translation of the target protein is activated in response to the abundance, i.e., expression level, of the small RNA in a small RNA-expressing system to express the protein. In this way, information conversion can be achieved from the "input" of the small RNA to the "output" of the protein.

The mRNA according to the first embodiment can perform gene translation in response to the presence of a small RNA and its abundance. Moreover, an intracellular small RNA expression level is known to vary depending on biological reactions in vivo. The mRNA according to this embodiment has the advantage that such change in small RNA expression level can be detected using the mRNA.

Next, according to the second embodiment, the present invention provides a liposome comprising an mRNA or DNA and a cell-free translational system encapsulated therein. Moreover, the present invention provides a method for producing a liposome comprising an mRNA or DNA and a cell-free translational system encapsulated therein, comprising the steps of: mixing one or more phospholipids, the mRNA and/or DNA, the cell-free translational system containing proteins, and an aqueous solution into an oily liquid to form a W/O emulsion in which the cell-free translational system is encapsulated in the phospholipid vesicle; adding an oily liquid containing outer membrane lipids dissolved therein, to an aqueous phase to form a molecular membrane in which the lipids are arranged at the oil/water interface; and adding the W/O emulsion to the oil phase side of the interface and spontaneously moving the W/O emulsion to the aqueous phase side of the interface such that the outer membrane lipid is added outside of the W/O emulsion to form a liposome.

The mRNA or DNA encapsulated in the liposome may be an mRNA having an arbitrary open reading frame or a DNA encoding the mRNA sequence. Thus, the mRNA according to the first embodiment may also be used. Any of those expressed into an arbitrary protein in the liposome can be used. Moreover, when the expressions of two or more proteins are desired, two or more different DNAs or a combination of mRNA(s) and DNA(s) may be used.

The cell-free translational system encapsulated in the liposome is a composition that can cause extracellular expression of the mRNA or DNA. This system comprises ribosomes, several types of protein factors, amino acids, and buffers, etc. One example thereof can include, but not limited to, enzymes, *E. coli* ribosomes, aminoacyl tRNA synthetases (20 kinds), T7 RNA polymerase, and buffers (50 mM Hepes-KOH, pH 7.6, 100 mM K-Glu, 2 mM spermidine, 13 mM Mg(OAc)<sub>2</sub>, 1 mM DTT, 0.3 mM each 20 amino acids, 560 D/ml tRNA mix, 10 mg/ml 10-formyl-5,6,7,8-tetrahydrofolic acid, 2 mM ATP, 2 mM GTP, 1 mM UTP, 1 mM CTP, 20 mM CP in terms of final concentrations). Specific components contained in the cell-free translational system are described in detail in Shimizu et al., *Methods* 36 (2005) 299-304. Those skilled in the art can construct the cell-free translational system based on the document. Particularly, a cell-free translational system comprising purified proteins is preferable. The cell-free translational system comprising purified proteins is preferably used in the liposome capable of constituting an artificial cell system according to this embodiment, because it is less likely to cause RNA decomposition owing to little RNase and has definite components.

The liposome comprising mRNA encapsulated therein can be produced based on the descriptions of PCT/JP2006/317517 and Langmuir 2006, 22, 9824-9828, which are incorporated herein by reference in their entirety.

Specifically, egg PC (egg-derived phosphatidyl choline) or a lipid selected from phosphatidyl serine and its derivatives and phosphatidyl ethanolamine and its derivatives, the mRNA or DNA encoding the mRNA sequence, an miRNA, the cell-free translational system containing proteins, and an aqueous solution are mixed into an oily liquid to form a W/O emulsion. Next, an oily liquid containing outer membrane lipids (egg PC or selected from phosphatidyl serine and its derivatives and phosphatidyl ethanolamine and its derivatives) dissolved therein is added to an aqueous phase to form a molecular membrane in which the outer membrane lipids are arranged at the oil/water interface.

In this context, the inner membrane phospholipid is preferably formulated to have a concentration of 0.5 mM to 0.75 mM in the oily liquid. When two or more inner membrane

phospholipids are used, the total concentration thereof is preferably set to this range. Moreover, the ratio between the oily liquid and the aqueous solution formulated is preferably set to aqueous solution/oily liquid=1/1000 to 1/10 by volume.

The oily liquid is not particularly limited as long as it stably disperses therein the inner membrane phospholipid. For example, mineral oil can be used. Examples of the aqueous solution can include, but not particularly limited to, liquids having properties necessary for containing the mRNA and causing the desired reaction.

Osmotic pressure conditions for maintaining an appropriate state in the liposome, specifically, without causing contraction or rupture preferably involve keeping the external pressure of the liposome smaller than the internal pressure thereof.

In this way, translational regulation or artificial information conversion can be performed intraliposomally by encapsulating the mRNA or DNA encoding the mRNA sequence, the miRNA, and the cell-free translational system containing proteins into the liposome. This enables construction of an artificial cell system. Moreover, likewise, translation reaction can be constructed intraliposomally by encapsulating the mRNA or DNA encoding the mRNA sequence and the cell-free translational system containing proteins into the liposome.

The thus-obtained liposome comprising the cell-free translational system tends to accumulate at the oil/water interface when formed through the steps. Therefore, many focused liposomes can be detected simultaneously under a microscope. Using this property, a modification of this embodiment provides a method for real-time monitoring of intraliposomal protein translation reaction, comprising the step of microscopically observing the liposome after the liposome formation step. This monitoring method has the advantage that it can allow real-time monitoring of intraliposomal switch ON/OFF of translation.

In this way, the second embodiment of the present invention has the advantage that a translation reaction system can be encapsulated in all liposomes. Moreover, since the liposomes remain at the oil/water interface, focused images of a plurality of liposomes can be obtained under a microscope. This also enables real-time monitoring of translation reaction within the plurality of liposomes.

Methods for constructing a translational regulatory system using an artificial RNA switch and introducing the artificial RNA switch into liposomes will be shown. This approach is a technique of constructing an artificial RNA switch system that causes structural change in response to a particular RNA to regulate gene translation reaction, and of introducing this artificial RNA switch to liposomes and regulating translation reaction in the liposomes. Hereinafter, a specific experimental example will be shown. The construction of the artificial RNA switch system is summarized as follows: an input substrate (small RNA, etc.) binds to the upstream "substrate RNA-recognizing RNA motif" inserted in the mRNA, and the binding between the substrate and the RNA motif induces the structural change of the mRNA translation initiation region such that the translation of a target protein (GFP, etc.) can be regulated depending on the binding of a ribosome to the mRNA.

Next, according to the third embodiment, the present invention provides an mRNA having a small RNA-binding site located 3' to the start codon. The mRNA according to this embodiment can function as an OFF switch mRNA that regulates translation in an ON-to-OFF manner in response to a small RNA.

FIG. 15 shows a schematic diagram of the mRNA according to this embodiment. The mRNA shown in FIG. 15 has a small RNA-binding site **3** located immediately 3' to a start codon AUG (**4a**). A nucleotide sequence **4b** encoding a gene of a protein to be expressed is located immediately 3' to the small RNA-binding site **3**. Specifically, in this mRNA, its open reading frame comprises the start codon AUG (**4a**), the small RNA-binding site **3**, and the nucleotide sequence **4b** encoding a gene of a protein to be expressed, in this order from the 5' side.

In this embodiment, the small RNA may be the arbitrary small RNA described in the first embodiment. In the description below, an miRNA is used as the small RNA. The small RNA-binding site **3** is a sequence complementary to an miRNA. This complementary sequence may have 1 to 3 mutations in some cases as long as it complementarily binds to the target miRNA. Examples of the cases particularly include the cases in which strong hydrogen bond can be formed when the site forming the complementary sequence is rich in GC. In this embodiment, the mRNA shown in the diagram has the small RNA-binding site **3** immediately 3' to the start codon AUG (**4a**) without additional bases intervening therebetween. However, additional bases may be located between the start codon AUG (**4a**) and the small RNA-binding site **3**. Specifically, relatively short bases such as approximately 3, 6, or 9 bases, whose base number is a multiple of 3 can also be present therebetween. The base number is set to a multiple of 3 for preventing the frameshift of translation.

The nucleotide sequence **4b** encoding a gene of a protein to be expressed may be a nucleotide sequence encoding a gene of an arbitrary protein. Examples of the protein include, but not limited to, fluorescent proteins serving as a marker, specifically, DsRed and EGFP. The mRNA shown in the diagram has the nucleotide sequence **4b** encoding a gene of a protein, immediately 3' to the small RNA-binding site **3** without additional bases intervening therebetween. However, when the base number of the small RNA-binding site **3** is not a multiple of 3, one or two bases are inserted between the small RNA-binding site **3** and the nucleotide sequence **4b** encoding a gene of a protein. This is because frameshift for the protein is prevented. Moreover, even when the base number of the small RNA-binding site **3** is a multiple of 3, additional bases may be present between the small RNA-binding site **3** and the nucleotide sequence **4b** encoding a gene of a protein. Specifically, relatively short bases such as approximately 3, 6, or 9 bases, whose base number is a multiple of 3 can also be present therebetween.

In the mRNA shown in FIG. 15, a ribosome-binding site 5' to the start codon AUG is not shown. However, the ribosome-binding site may be present or may be absent for mRNAs derived from eukaryotic cells.

The mRNA thus constituted according to the third embodiment of the present invention functions as an OFF switch mRNA in the presence of a particular small RNA. The functions of such an mRNA will be described below.

In the absence of the particular small RNA, i.e., an miRNA **6** specifically binding to the mRNA according to the third embodiment, the mRNA is translated under conditions involving 25 to 42° C. and pH 6 to 8.5 to form the desired protein having, at the N terminus, an amino acid encoded by the miRNA. By the addition of the miRNA **6** thereto, the miRNA **6** forms a complementary double strand through its specific binding with the mRNA designed to have a sequence specifically binding thereto (small RNA-binding site **3**). A schematic diagram of the molecule in this state is shown in FIG. 16. As a result, ribosome-catalyzed mRNA translation is inhibited to repress protein expression.

In this way, the use of the mRNA according to this embodiment and the small RNA specifically binding thereto enables ON-to-OFF regulation of protein translation. Accordingly, examples of modifications of the third embodiment include a translation/expression regulation system comprising the mRNA thus constituted and a small RNA specifically binding thereto, and a method for translational regulation of mRNA, comprising mixing the mRNA with a small RNA complementarily binding to the small RNA-binding site.

The applicative aspect of this embodiment can achieve translational regulation within PURE system and is useful as a tool for artificial signal cells.

Furthermore, in an artificial information conversion method, owing to the properties of the mRNA according to the third embodiment, the translation of the target protein is repressed in response to the abundance, i.e., expression level, of the small RNA in a small RNA-expressing system to inhibit protein expression. In this way, information conversion can be achieved from the "input" of the small RNA to the "output" of the protein.

Next, the fourth embodiment of the present invention will be described. The fourth embodiment of the present invention relates to an artificial translational system. Specifically, it relates to an artificial translational system comprising the ON switch mRNA described in the first embodiment, the OFF switch mRNA described in the third embodiment, a small RNA specifically binding to both the mRNAs.

FIG. 17(A) shows a schematic diagram of the ON switch mRNA constituting the artificial translational system according to this embodiment; FIG. 17(B) shows a schematic diagram of the OFF switch mRNA constituting it; and FIG. 17(C) shows a schematic diagram of the small RNA constituting it. In this embodiment, the case will be illustrated in which a protein expressed by the ON switch mRNA is DsRed and a protein expressed by the OFF switch mRNA is EGFP. However, this combination of the expressed proteins is shown for illustrative purposes and is not intended to limit the present invention.

The ON switch mRNA of this embodiment, as shown in the diagram, comprises a DsRed-encoding nucleotide sequence **40** located immediately 3' to a ribosome-binding site **20** and a sequence **30** located 5' to the ribosome-binding site, the sequence **30** being complementary to a small RNA. The ON switch mRNA further comprises, 5' thereto, a sequence **50** complementary to the ribosome-binding site. This ON switch mRNA forms a stem-loop structure, as shown in FIG. 17(A), in the absence of a small RNA **60**. In this case, the ribosome-binding site **20** is blocked. Therefore, the ON switch mRNA in this state is not translated even under translatable conditions, resulting in no DsRed production.

On the other hand, the OFF switch mRNA of this embodiment, as shown in FIG. 17(B), comprises a sequence **30** located immediately 3' to a start codon AUG (**41a**), the sequence **30** being complementary to a small RNA **60**. The OFF switch mRNA further comprises an EGFP-encoding nucleotide sequence **41b** located 3' to the sequence **30** complementary to a small RNA **60**. Moreover, a ribosome-binding site may be present (not shown) 5' to the start codon AUG (**41a**) or may be absent. Such an OFF switch mRNA is translated under translatable conditions in the absence of the small RNA **60** to produce the protein EGFP.

The small RNA **60** shown in FIG. 17(C) is a sequence capable of forming a complementary strand through its specific binding to the sequence **30** complementary to the small RNA **60**, both in the ON switch mRNA and in the OFF switch mRNA.

## 13

Next, FIG. 18 schematically showing the state of each molecule in the coexistence of the ON switch mRNA, the OFF switch mRNA, and the small RNA 60. In the ON switch mRNA shown in FIG. 18(A), the small RNA 60 forms a complementary strand through its specific binding to the sequence 30 having a loop structure in FIG. 17(A). As a result, the stem-loop structure is deformed, and the ribosome-binding site 20 is in turn placed in a state capable of binding to a ribosome. On the other hand, in the OFF switch mRNA shown in FIG. 18(B), the small RNA 60 forms a complementary strand through its specific binding to the sequence 30 located immediately downstream of the start codon. As a result, the OFF switch mRNA shown in FIG. 18(B) cannot be translated in this state.

In such a state, which is a translatable state, shown in FIG. 18(A), a ribosome can bind to the ON switch mRNA. Accordingly, the gene in the open reading frame 40 is expressed in the presence of the ribosome and under appropriate other conditions to produce DsRed. On the other hand, in the OFF switch mRNA, a double strand is formed immediately downstream of the start codon. Therefore, the mRNA cannot be translated. As a result, EGFP encoded by the sequence 41*b* is not produced.

In this way, according to the fourth embodiment, two mRNAs differing in behavior in response to the presence of the same small RNA can be used as switches.

The applicative aspect of this embodiment can achieve translational regulation within PURE system and is useful as a tool for artificial signal cells.

Furthermore, in an artificial information conversion method, owing to the properties of the ON switch mRNA and the OFF switch mRNA according to the fourth embodiment, the translation of the target protein encoded by the ON switch mRNA is activated in response to the abundance, i.e., expression level, of the small RNA in a small RNA-expressing system to express the protein. At the same time, the translation of another target protein encoded by the OFF switch mRNA is repressed in response to the abundance, i.e., expression level, of the small RNA to inhibit protein expression. In this way, information conversion can be achieved from the “input” of the small RNA to the separate “outputs” of two different proteins.

Next, the fifth embodiment of the present invention will be described. The fifth embodiment provides an mRNA that functions as an ON switch in response to the addition of a small RNA. The mRNA according to this embodiment is referred to as a double ON switch mRNA.

FIG. 19 schematically shows the secondary structure of the mRNA according to this embodiment. The mRNA according to this embodiment comprises a small RNA-binding site 3, a sequence 5 complementary to the ribosome-binding site, another small RNA-binding site 3, a ribosome-binding site 2, and an open reading frame 4, in this order from the 5' side. The open reading frame 4 comprises a start codon AUG 4*a*, a sequence 8 complementarily binding to a portion of the small RNA-binding site 3, and a nucleotide sequence 4*b* encoding a gene of a protein to be expressed, in this order from the 5' side.

In this context, each small RNA-binding site 3 can have a nucleotide sequence that forms a reverse complement of a particular small RNA. This complementary sequence may have 1 to 3 mutations in some cases as long as it complementarily bind to the target small RNA. Moreover, these two small RNA-binding sites 3 preferably have identical sequences.

The sequence 8 complementarily binding to a portion of the small RNA-binding site 3 has a sequence identical to at least 6 consecutive bases of the particular small RNA. The number of the consecutive bases is preferably 6 bases or more

## 14

and is a multiple of 3 equal to or smaller than the base number of the small RNA. Specifically, the number of the consecutive bases is preferably set to approximately 6 bases, 9 bases, 12 bases, 15 bases, or 18 bases, though the base number is not limited thereto. The reason for such a constitution is that a complementary strand is formed with the small RNA while frameshift of the protein to be expressed is prevented. The sequence 8 complementarily binding to a portion of the small RNA-binding site 3 may comprise a sequence identical to the particular small RNA and an additional sequence. In such a case as well, the base number of the sequence 8 is a multiple of 3.

The mRNA shown in FIG. 19 forms a stem-loop structure, as shown in the diagram, in the absence of the particular small RNA. In this case, the stem moiety contains a first complementary strand moiety formed by the sequence 5 complementary to the ribosome-binding site and the ribosome-binding site 2 and a second complementary strand moiety formed by the small RNA-binding site 3 and the sequence 8 complementarily binding to a portion of the small RNA-binding site 3. The ribosome-binding site 2 is blocked by the formed complementary strand. Therefore, a ribosome, if any, cannot bind to the ribosome-binding site 2. Accordingly, the double ON switch mRNA in this state is not translated even under translatable conditions, resulting in no production of the protein encoded by the sequence 4*b*.

In the mRNA according to the fifth embodiment, the advantage of the presence of the first and second complementary strand moieties is that owing to the action of these two complementary strands, a stable OFF state can be formed in the absence of the particular small RNA and an ON state can be formed efficiently in the presence of the small RNA.

Next, FIG. 20 schematically shows the secondary structure of the mRNA coexisting with particular small RNAs 6. In this case, the particular small RNAs 6 specifically bind to both the two small RNA-binding sites 3 on the mRNA to form complementary strands. As a result, the stem-loop structure is deformed such that the ribosome-binding site 2 is unblocked. Accordingly, translation proceeds in the presence of the ribosome and under appropriate other conditions to produce the protein encoded by the nucleotide sequence 4*b*.

In this way, the fifth embodiment has the advantage that depending on the sequences of the small RNA-binding sites, the first and second complementary strand moieties can act cooperatively to prepare an efficient OFF-to-ON switch, when the mRNA structure cannot form stable OFF and ON states.

## Example 1

[Preparation of Original EGFP and RNA-Responsive Artificial RNA Switches]

Original EGFP and RNA-responsive artificial RNAs (EGFP) were prepared (EGFP, SEQ ID NO: 1) by performing twice or three times PCR using pEGFP (manufactured by Clontech). All primers described here were synthesized by Hokkaido System Science Co., Ltd.

[Preparation of Original EGFPmRNA]

pEGFP was used as a template to perform 1st PCR using EGFP fwd (SEQ ID NO: 2) and EGFP rev (SEQ ID NO: 3) as primers. 50  $\mu$ L of reaction solution contained a mixture of 25 ng of pEGFP, 1.5  $\mu$ L of 10  $\mu$ M each DNA primers, 5  $\mu$ L of 2 mM dNTPs, 5  $\mu$ L of 10 $\times$ KOD-PLUS-buffer ver. 2, 2  $\mu$ L of 25 mM MgSO<sub>4</sub>, and 1  $\mu$ L of KOD-PLUS-DNA polymerase. Reaction was performed by initially performing incubation at 94 $^{\circ}$  C. for 2 minutes and then 20 cycles each involving 94 $^{\circ}$  C. for 15 seconds, 50 $^{\circ}$  C. for 30 seconds, and 68 $^{\circ}$  C. for 1 minute.

In the description below, only a template and primers will be shown because PCR was performed under the same conditions as above.

After the reaction, the reaction solution was subjected to phenol treatment and ethanol precipitation and dissolved in a non-denaturing dye (30% glycerin, 0.075% xylene cyanol, 0.075% bromophenol blue, 69.85% ultrapure water). The band of interest was separated and excised using low melting point agarose SEAPLAQUE GTG AGAROSE (FMC Corp.). The excised agarose fragment was supplemented with 200  $\mu$ L of TE, then incubated at 65° C. for 30 min, and then subjected to 3 phenol treatments, diethyl ether treatment, and ethanol precipitation for DNA purification (EGFP 1st PCR, SEQ ID NO: 4). Next, EGFP 1st PCR was used as a template to perform 2nd PCR in the same way as above using Universal primer (SEQ ID NO: 5) and EGFP Rev as primers. After the reaction, separation and purification were performed in the same way as above, and the purification product was dissolved in ultrapure water, followed by concentration measurement using DU640 SPECTROPHOTOMETER (manufactured by Beckman Coulter, Inc.). This product is referred to as Original EGFP template (SEQ ID NO: 6). Original EGFP template was used as a template to perform transcription reaction using MEGAshortscript (trademark) (manufactured by Ambion, Inc.). The transcription reaction using MEGAshortscript was performed as follows. 1  $\mu$ g of template DNA dissolved in ultrapure water, 2  $\mu$ L of T7 10 $\times$  Reaction Buffer, 2  $\mu$ L of T7 ATP Solution (75 mM) (the same recipe for CTP, GTP, and UTP), and 2  $\mu$ L of T7 Enzyme Mix were mixed and adjusted with ultrapure water to the whole amount of 20  $\mu$ L. This reaction solution was reacted at 37° C. for 4 hours to overnight. After the reaction, the solution was supplemented with 1  $\mu$ L of TURBO DNase and incubated at 37° C. for 15 minutes to decompose the template DNA. Original EGFP mRNA (SEQ ID NO: 7) obtained through the transcription reaction was purified using RNeasy MinElute (trademark) Cleanup Kit (QIAGEN GmbH). The purification using RNeasy MinElute (trademark) Cleanup Kit was performed as follows.

The transcription reaction solution was adjusted to 100  $\mu$ L by the addition of 80  $\mu$ L of ultrapure water, further supplemented with 350  $\mu$ L of Buffer RLT, and sufficiently mixed. 250  $\mu$ L of ethanol was added thereto and completely mixed by pipetting. The sample was applied to RNeasy MinElute Spin Column loaded in a 2-mL collection tube and centrifuged at 10,000 rpm for 15 seconds using a high-speed refrigerated microcentrifuge MX-100 (manufactured by TOMY SEIKO CO., LTD.), and the flow-through fraction was discarded. The spin column was transferred to a new 2-ml collection tube, and 500  $\mu$ L of Buffer RPE was added onto the spin column using a pipette. The sample was centrifuged at 10,000 rpm for 15 seconds, and the flow-through fraction was discarded. After addition of 500  $\mu$ L of 80% ethanol to the RNeasy MinElute Spin Column, the sample was centrifuged at 10,000 rpm for 2 minutes, and the flow-through fraction was discarded. The RNeasy MinElute Spin Column was transferred to a new 2-ml collection tube. The sample was centrifuged at 14,000 rpm for 5 minutes with the spin column cap opened, and the flow-through fraction was discarded. The spin column was transferred to a new 1.5-ml collection tube, and 20  $\mu$ L of ultrapure water was added to the center of the silica gel membrane. The sample was centrifuged at 14,000 rpm for 5 minutes for elution. This eluate was used in concentration measurement using DU640 SPECTROPHOTOMETER.

[Preparation of RNA-Responsive Artificial RNA (5' miR164-Responsive EGFP)]

EGFP 1st PCR was used as a template to perform 2nd PCR in the same way as above using 5' UTR-miRNA164 fwd (SEQ ID NO: 8) and EGFP rev as primers. After the reaction, separation and purification were performed in the same way as above. This product is referred to as 5' miR164-responsive EGFP 2nd PCR (SEQ ID NO: 9). Next, 5' miR164-responsive EGFP 2nd PCR was used as a template to perform 3rd PCR in the same way as above using T7-stem-loop uni (SEQ ID NO: 10) and EGFP rev as primers. After the reaction, separation and purification were performed in the same way as above, and the purification product was dissolved in ultrapure water, followed by concentration measurement using DU640 SPECTROPHOTOMETER. This product is referred to as 5' miR164-responsive EGFP template (SEQ ID NO: 11). 5' miR164-responsive EGFP template was used as a template to perform transcription reaction in the same way as above using MEGAshortscript (trademark). 5' miR164-responsive EGFP mRNA (SEQ ID NO: 12) obtained through the transcription reaction was purified in the same way as above using RNeasy MinElute (trademark) Cleanup Kit, followed by concentration measurement. FIG. 3B is a schematic diagram showing the secondary structure of the 5' miR164-responsive EGFP mRNA. FIG. 3A is a diagram showing miRNA164.

[Preparation of RNA-Responsive Artificial RNA (5' miR164-Responsive DsRed-Monomer)]

An RNA-responsive artificial RNA (DsRed-Monomer) was prepared by performing three times PCR using pDsRed-Monomer (manufactured by Clontech) (DsRed-Monomer, SEQ ID NO: 13). pDsRed-Monomer was used as a template to perform 1st PCR in the same way as above using DsRed-Monomer fwd (SEQ ID NO: 14) and DsRed-Monomer rev (SEQ ID NO: 15) as primers. After the reaction, separation and purification were performed in the same way as above. This product is referred to as DsRed-Monomer 1st PCR (SEQ ID NO: 16). Next, DsRed-Monomer 1st PCR was used as a template to perform 2nd PCR in the same way as above using 5' UTR-miRNA164 fwd and DsRed-Monomer rev as primers. After the reaction, separation and purification were performed in the same way as above. This product is referred to as 5' miR164-responsive DsRed-Monomer 2nd PCR (SEQ ID NO: 17). Further, 5' miR164-responsive DsRed-Monomer 2nd PCR was used as a template to perform 3rd PCR in the same way as above using T7-stem-loop uni and DsRed-Monomer rev as primers. After the reaction, separation and purification were performed in the same way as above, and the purification product was dissolved in ultrapure water, followed by concentration measurement using DU640 SPECTROPHOTOMETER. This product is referred to as 5' miR164-responsive DsRed-Monomer template (SEQ ID NO: 18). 5' miR164-responsive DsRed-Monomer template was used as a template to perform transcription reaction in the same way as above using MEGAshortscript (trademark). 5' miR164-responsive DsRed-Monomer mRNA (SEQ ID NO: 19) obtained through the transcription reaction was purified in the same way as above using RNeasy MinElute (trademark) Cleanup Kit, followed by concentration measurement. [Preparation of RNA-Responsive Artificial RNA (5' miR170-Responsive EGFP)]

EGFP 1st PCR was used as a template to perform 2nd PCR in the same way as above using 5' UTR-miRNA170 fwd (SEQ ID NO: 20) and EGFP rev as primers. After the reaction, separation and purification were performed in the same way as above. This product is referred to as 5' miR170-responsive EGFP 2nd PCR (SEQ ID NO: 21). Next, 5' miR170-responsive EGFP 2nd PCR was used as a template to perform 3rd

PCR in the same way as above using T7-stem-loop uni and EGFP rev as primers. After the reaction, separation and purification were performed in the same way as above, and the purification product was dissolved in ultrapure water, followed by concentration measurement using DU640 SPECTROPHOTOMETER. This product is referred to as 5' miR170-responsive EGFP template (SEQ ID NO: 22). 5' miR170-responsive EGFP template was used as a template to perform transcription reaction in the same way as above using MEGAshortscript (trademark). 5' miR170-responsive EGFP mRNA (SEQ ID NO: 23) obtained through the transcription reaction was purified in the same way as above using RNeasy MinElute (trademark) Cleanup Kit, followed by concentration measurement.

[Preparation of RNA-Responsive Artificial RNA (5' miR171-Responsive EGFP)]

EGFP 1st PCR was used as a template to perform 2nd PCR in the same way as above using 5' UTR-miRNA171 fwd (SEQ ID NO: 24) and EGFP rev as primers. After the reaction, separation and purification were performed in the same way as above. This product is referred to as 5' miR171-responsive EGFP 2nd PCR (SEQ ID NO: 25). Next, 5' miR171-responsive EGFP 2nd PCR was used as a template to perform 3rd PCR in the same way as above using T7-stem-loop uni and EGFP rev as primers. After the reaction, separation and purification were performed in the same way as above, and the purification product was dissolved in ultrapure water, followed by concentration measurement using DU640 SPECTROPHOTOMETER. This product is referred to as 5' miR171-responsive EGFP template (SEQ ID NO: 26). 5' miR171-responsive EGFP template was used as a template to perform transcription reaction in the same way as above using MEGAshortscript (trademark). 5' miR171-responsive EGFP mRNA (SEQ ID NO: 27) obtained through the transcription reaction was purified in the same way as above using RNeasy MinElute (trademark) Cleanup Kit, followed by concentration measurement.

### Example 2

[Translational Regulation Assay Using Cell-Free Expression System of RNA-Responsive Artificial RNA Switch]

A cell-free expression system PURE system was used for confirming the translational regulation of an RNA-responsive artificial RNA switch. The PURE system is composed of Solution A and Solution B. In the description below, these solutions are simply referred to as Solutions A and B, respectively. Solution A has the composition involving 100 mM Hepes-KOH (pH 7.6), 200 mM L-Glutamic acid Monopotassium salt, 4 mM spermidine, 26 mM Mg(OAc)<sub>2</sub>, 2 mM DTT, 1120 D/ml tRNA mix, 20 µg/ml 10-formyl-5,6,7,8-tetrahydrofolic acid, 4 mM ATP, 4 mM GTP, 2 mM CTP, 2 mM UTP, 40 mM creatine phosphate, and 0.6 mM each 20 amino acids. Solution B is composed mainly of T7 RNA polymerase, IF1, IF2, IF3, EF-G, EF-Tu, EF-Ts, RF1, RF2, RF3, RRF, etc., which are proteins necessary for transcription and translation. Hereinafter, assay on each RNA-responsive artificial RNA switch and its results will be shown.

[Assay on 5' miR164-Responsive EGFP]

Five solutions each containing a mixture of 1 µL of 20 µM 5' miR164-responsive EGFP, 1 µL of ultrapure water, 5 µL of Solution A, and 2 µL of Solution B were prepared and supplemented with 1 µL each of 40 µM, 20 µM, 10 µM, 5 µM, and 0 µM synthesized miRNA164 (Hokkaido System Science Co., Ltd., SEQ ID NO: 29), respectively, to adjust the whole amount of 10 µL. The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with

ultrapure water to 200 µL and measured at an excitation wavelength of 485 nm and an absorption wavelength of 535 nm using infinite F200 (manufactured by TECAN Trading AG) (FIG. 4).

For negative controls, five solutions each containing a mixture of 1 µL of 20 µM 5' miR164-responsive EGFP, 1 µL of ultrapure water, 5 µL of Solution A, and 2 µL of Solution B were prepared and supplemented with 1 µL each of 40 µM, 20 µM, 10 µM, 5 µM, and 0 µM synthesized miRNA163 (Hokkaido System Science Co., Ltd., SEQ ID NO: 28), respectively, to adjust the whole amount of 10 µL. The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with ultrapure water to 200 µL and measured at an excitation wavelength of 485 nm and an absorption wavelength of 535 nm using infinite F200 (TECAN Trading AG) (FIG. 4). This assay demonstrated that this RNA-responsive artificial RNA switch (5' miR164-responsive EGFP) specifically reacts with miRNA164 to perform translational regulation.

[Assay on 5' miR164-Responsive DsRed-Monomer]

Four solutions each containing a mixture of 1 µL of 10 µM 5' miR164-responsive DsRed-Monomer, 1 µL of ultrapure water, 5 µL of Solution A, and 2 µL of Solution B were prepared and supplemented with 1 µL each of 40 µM, 20 µM, 10 µM, and 0 µM miRNA164, respectively, to adjust the whole amount of 10 µL. The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with ultrapure water to 200 µL and measured at an excitation wavelength of 535 nm and an absorption wavelength of 595 nm using infinite F200 (manufactured by TECAN Trading AG) (FIG. 5). This assay demonstrated that these RNA-responsive artificial RNA switches (5' miR164-responsive EGFP and 5' miR164-responsive DsRed-Monomer) are independent of the sequence of the open reading frame.

[Assay on 5' miR171-Responsive EGFP]

Three solutions each containing a mixture of 1 µL of 2 µM 5' miR171-responsive EGFP, 1 µL of ultrapure water, 5 µL of Solution A, and 2 µL of Solution B were prepared and supplemented with 1 µL each of 40 µM, 10 µM, and 0 µM synthesized miRNA171 (Hokkaido System Science Co., Ltd., SEQ ID NO: 31), respectively, to adjust the whole amount of 10 µL. The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with ultrapure water to 200 µL and measured at an excitation wavelength of 485 nm and an absorption wavelength of 535 nm using infinite F200 (manufactured by TECAN Trading AG) (FIG. 6). For controls, six solutions each containing a mixture of 1 µL of 2 µM 5' miR171-responsive EGFP, 1 µL of ultrapure water, 5 µL of Solution A, and 2 µL of Solution B were prepared and supplemented with 1 µL each of 40 µM and 10 µM synthesized miRNA170 (Hokkaido System Science Co., Ltd., SEQ ID NO: 30), miRNA163, or miRNA164, respectively, to adjust the whole amount of 10 µL. The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with ultrapure water to 200 µL and measured at an excitation wavelength of 485 nm and an absorption wavelength of 535 nm using infinite F200 (TECAN Trading AG) (FIG. 6). This assay demonstrated that this RNA-responsive artificial RNA switch (5' miR171-responsive EGFP) specifically reacts with miRNA171 and exhibits different translational efficiency even for miRNA170 differing therefrom only by 2 bases.

[Assay on 5' miR170-Responsive EGFP]

Three solutions each containing a mixture of 1 µL of 2 µM 5' miR170-responsive EGFP, 1 µL of ultrapure water, 5 µL of Solution A, and 2 µL of Solution B were prepared and supplemented with 1 µL each of 10 µM, 5 µM, and 0 µM miRNA170,

respectively, to adjust the whole amount of 10  $\mu\text{L}$ . The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with ultrapure water to 200  $\mu\text{L}$  and measured at an excitation wavelength of 485 nm and an absorption wavelength of 535 nm using infinite F200 (manufactured by TECAN Trading AG) (FIG. 7). For controls, three solutions each containing a mixture of 1  $\mu\text{L}$  of 2  $\mu\text{M}$  5' miR170-responsive EGFP, 1  $\mu\text{L}$  of ultrapure water, 5  $\mu\text{L}$  of Solution A, and 2  $\mu\text{L}$  of Solution B were prepared and supplemented with 1  $\mu\text{L}$  each of 10  $\mu\text{M}$ , 5  $\mu\text{M}$ , and 0  $\mu\text{M}$  synthesized miRNA171, respectively, to adjust the whole amount of 10  $\mu\text{L}$ . The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with ultrapure water to 200  $\mu\text{L}$  and measured at an excitation wavelength of 485 nm and an absorption wavelength of 535 nm using infinite F200 (manufactured by TECAN Trading AG) (FIG. 7). This assay demonstrated that this RNA-responsive artificial RNA switch (5' miR170-responsive EGFP) specifically reacts with miRNA170 and exhibits different translational efficiency even for miRNA171 differing therefrom only by 2 bases.

### Example 3

[Preparation of Liposome Comprising Gene and Cell-Free Expression System Encapsulated Therein and Confirmation of Expression]

[Method for Preparing Liposome Comprising Gene and Cell-Free Expression System Encapsulated Therein]

L- $\alpha$ -Phosphatidyl choline (Egg, Chicken) (manufactured by Avanti Polar Lipids, Inc. Polar Lipids, Inc.) was dissolved in a methanol:chloroform=1:2 solution to prepare a 10 mM organic solution of egg PC. 25 to 37.5  $\mu\text{L}$  aliquots of the 10 mM egg PC solution were separately placed in Durham tubes (manufactured by Maruemu Corp.), and the methanol:chloroform solution was evaporated by the spray of nitrogen gas (manufactured by Taiyo Nippon Sanso Corp.) to form lipid films. Each Durham tube with the lipid films thus formed was wrapped in aluminum foil and placed in a desiccator, to which the vacuum was then applied for 10 minutes using a diaphragm dry vacuum pump DA-40S (manufactured by ULVAC, Inc.). Then, 500  $\mu\text{L}$  of mineral oil (manufactured by Nacalai Tesque, Inc.) was added thereto, and the tube was sealed with Parafilm and sonicated at 50° C. for 60 minutes using an ultrasonic cleaner US-1KS (manufactured by SND Co., Ltd.). Immediately after the sonication, the tube was shaken for 20 seconds by vortexing. 0.5 to 0.75 mM egg PC solutions were thus prepared. PDMS was used as a chamber for microscopic observation. FIG. 8 schematically shows the chamber. In FIG. 8, 10  $\mu\text{L}$  of Feeding solution 13 (the details will be described later) was placed in a hole of a PDMS chamber 10 loaded in a cover glass. Then, 10  $\mu\text{L}$  of the egg PC solution 12 thus prepared was gently applied thereonto and left standing for 1 hour. 2.5  $\mu\text{L}$  of Liposome inside solution 15 (the details will be described later) was added to 50  $\mu\text{L}$  of egg PC solution 11, and a W/O emulsion was formed by pipetting. The emulsion 14 was applied onto the Feeding solution-egg PC solution thus left standing to form a liposome 16 (FIG. 9). The PDMS chamber was transferred for observation onto a confocal laser scanning microscope LSM510 (Carl Zeiss Microimaging Inc.) equipped with Thermo Plate (TOKAI HIT COMPANY) set to 37° C.

[Study on Conditions for Feeding Solution and Liposome Inside Solution]

Change in liposome formation ability and in intraliposomal translational efficiency depending on the difference in osmotic pressure between Feeding solution and Liposome inside solution was studied by comparison among a total of 6

combinations involving 3 kinds of Feeding solutions and 2 kinds of Liposome inside solutions. These 3 kinds of Feeding solutions were prepared as

- (A) Solution A 9.6  $\mu\text{L}$ +Pure mix (mixture of Solution A 5  $\mu\text{L}$ +Solution B 2  $\mu\text{L}$ +ultrapure water 3  $\mu\text{L}$ ) 0.4  $\mu\text{L}$ ,
- (B) Solution A 5  $\mu\text{L}$ +ultrapure water 5  $\mu\text{L}$ , and
- (C) Solution A 5  $\mu\text{L}$ +ultrapure water 4.6  $\mu\text{L}$ +Pure mix 0.4  $\mu\text{L}$ .

Each Feeding solution has the following buffer concentration:

- (A) 98 mM Hepes-KOH (pH 7.6), 196 mM L-Glutamic acid Monopotassium salt, 3.92 mM spermidine, 25.48 mM Mg(OAc)<sub>2</sub>, 1.96 mM DTT,
- (B) 50 mM Hepes-KOH (pH 7.6), 100 mM L-Glutamic acid Monopotassium salt, 2 mM spermidine, 13 mM Mg(OAc)<sub>2</sub>, 1 mM DTT, and
- (C) 52 mM Hepes-KOH (pH 7.6), 104 mM L-Glutamic acid Monopotassium salt, 2.08 mM spermidine, 13.52 mM Mg(OAc)<sub>2</sub>, 1.04 mM DTT.

The 2 kinds of Liposome inside solutions were prepared as 1. Pure (2  $\mu\text{g}/\mu\text{L}$  Original EGFP template DNA 1  $\mu\text{L}$ +ultrapure water 2  $\mu\text{L}$ +Solution A 5  $\mu\text{L}$ +Solution B 2  $\mu\text{L}$ ) 100%, and

- 2. Pure (2  $\mu\text{g}/\mu\text{L}$  Original EGFP template DNA 1  $\mu\text{L}$ +ultrapure water 2  $\mu\text{L}$ +Solution A 5  $\mu\text{L}$ +Solution B 2  $\mu\text{L}$ ) 50%+2-fold diluted Solution A 50% (ultrapure water 5  $\mu\text{L}$ +Solution A 5  $\mu\text{L}$ ) 50%.

Each Liposome inside solution has the following buffer concentration:

- 1. 50 mM Hepes-KOH (pH 7.6), 100 mM L-Glutamic acid Monopotassium salt, 2 mM spermidine, 13 mM Mg(OAc)<sub>2</sub>, 1 mM DTT, and
- 2. 50 mM Hepes-KOH (pH 7.6), 100 mM L-Glutamic acid Monopotassium salt, 2 mM spermidine, 13 mM Mg(OAc)<sub>2</sub>, 1 mM DTT.

First, to compare liposome formation ability, these 2 kinds of Liposome inside solutions were incubated, for EGFP expression, at 37° C. in advance before liposome formation, and liposomes were then prepared. The 3 kinds of Feeding solutions and a 0.5 mM egg PC solution were used. The results demonstrated that a larger number of larger liposomes can be formed by preparation using the Feeding solution (B) or (C) Solution A 5  $\mu\text{L}$ +ultrapure water 4.6  $\mu\text{L}$ +Pure mix 0.4  $\mu\text{L}$  than using the Feeding solution (A) having high osmotic pressure.

Next, an EGFP-encoding DNA was encapsulated in liposomes under conditions involving Feeding solution (A) and Liposome inside solution 2, and 1 hour later, EGFP expression within the liposomes was confirmed. FIG. 11(A) is a photograph showing fluorescence within the liposomes, and FIG. 11(B) is a bright-field microscopic image showing that the liposomes 16 are present. DNA-free liposomes were also stably present after 1 hour (FIG. 10(B)) but do not emit fluorescence (FIG. 10(A)). In FIGS. 10(B) and 11(B), the liposomes were contoured for clearly showing their outlines.

Next, to confirm difference in intraliposomal translational efficiency, the 3 kinds of Feeding solutions, a 0.5 mM egg PC solution, and the 2 kinds of Liposome inside solutions were used to form liposomes, which were then incubated at 37° C. A microscopic photograph after 60 minutes is shown in FIG. 12. As a result, of the two kinds of Liposome inside solutions, Pure 100% offered larger fluorescence intensity. Of the 3 kinds of Feeding Solutions, the Feeding solution (A) offered larger fluorescence intensity than that offered by the other Feeding solutions (B) and (C). However, in terms of the number or size of the liposomes, a larger number of larger

## 21

liposomes were formed using the Feeding solution (B) or (C) than using the Feeding solution (A), as in the results described above.

In consideration of these results, it was determined that (C) Solution A 5  $\mu$ L+ultrapure water 4.6  $\mu$ L+Pure mix 0.4  $\mu$ L was used as Feeding solution while 1. Pure 100% was used as Liposome inside solution.

[Confirmation of Intraliposomal Original EGFP Template Expression Based on Time Lapse]

First, Original EGFP was used to confirm that time-lapse gene expression necessary for analyzing the efficiency, duration, or the like of an RNA-responsive artificial RNA switch can be achieved intraliposomally. (C) Solution A 5  $\mu$ L+ultrapure water 4.6  $\mu$ L+Pure mix 0.4  $\mu$ L was used as Feeding solution. An egg PC solution was used at a concentration of 0.75 mM. 1. Pure 100% was used as Liposome inside solution. The results are shown in FIG. 13. As is evident therefrom, intraliposomal fluorescence that was not observed at 0 min was observed more brightly and more clearly with a lapse of 15 minutes and distinctly observed at 135 min. These results demonstrated that time-lapse expression can be achieved intraliposomally.

## Example 4

[Confirmation of Intraliposomal Translational Regulation of RNA-Responsive Artificial RNA Switch]

[Time-Lapse Intraliposomal Translational Regulation of 5' miR164-Responsive EGFP]

It was confirmed based on time lapse that the translational regulation of 5' miR164-responsive EGFP as an RNA-responsive artificial RNA switch can be achieved intraliposomally. (C) Solution A 5  $\mu$ L+ultrapure water 4.6  $\mu$ L+Pure mix 0.4  $\mu$ L was used as Feeding solution. An egg PC solution was used at a concentration of 0.75 mM. 30  $\mu$ M 5' miR164-responsive EGFP 1  $\mu$ L+60  $\mu$ M miRNA164 1  $\mu$ L+ultrapure water 1  $\mu$ L+Solution A 5  $\mu$ L+Solution B 2  $\mu$ L was used as Liposome inside solution. The results are shown in FIG. 14. In the drawing, intraliposomal fluorescence was not observed at 0 min, whereas distinct fluorescence could be observed at 60 min. This means that gene translation was switched ON depending on the presence of the miRNA to form the fluorescent protein. These results demonstrated that the translational regulation of the RNA-responsive artificial RNA switch can be achieved intraliposomally.

## Example 5

RNA-responsive artificial RNA switches as ON switches were prepared and assayed for their translational regulations. [Preparation of RNA-Responsive Artificial RNA Switches]

5' miR164-responsive EGFP and 5' miR164-responsive DsRed Monomer were prepared in the same way as in Example 1. miR164, an miRNA complementarily binding to each of them, was purchased from Hokkaido System Science Co., Ltd.

5' miR156-responsive EGFP (SEQ ID NO: 32) was prepared in the same way as in Example 1.

Specifically, all template DNAs for artificial RNA switches were prepared by performing twice or three times PCR using Gradient Master Cycler (Eppendorf). All PCR reactions were performed according to the following protocol using KOD-PLUS-(TOYOBO CO., LTD.). 50  $\mu$ L of PCR reaction solution contained a mixture of 25 ng of template DNA, 1.5  $\mu$ L of 10  $\mu$ M each DNA primers, 5  $\mu$ L of 2 mM dNTPs, 5  $\mu$ L of 10 $\times$ KOD-PLUS-buffer ver. 2, 2  $\mu$ L of 25 mM MgSO<sub>4</sub>, and 1  $\mu$ L of KOD-PLUS-DNA polymerase. Reaction was per-

## 22

formed by initially performing incubation at 94° C. for 2 minutes and then 20 cycles each involving 94° C. for 15 seconds, 50° C. for 30 seconds, and 68° C. for 1 minute. After the reaction, the reaction solution was subjected to phenol treatment and ethanol precipitation and dissolved in a non-denaturing dye (30% glycerin, 0.075% xylene cyanol, 0.075% bromophenol blue, 69.85% ultrapure water). The band of interest was separated and excised using low melting point agarose SEAPLAQUE GTG AGAROSE (FMC Corp.). The excised agarose fragment was supplemented with 200  $\mu$ L of TE, then incubated at 65° C. for 30 minutes, and then subjected to 3 phenol treatments, diethyl ether treatment, and ethanol precipitation for DNA purification. The purification product was dissolved in ultrapure water, followed by concentration measurement using DU640 SPECTROPHOTOMETER (Beckman Coulter, Inc.).

Each template DNA thus prepared was used to perform transcription reaction using MEGAscript (trademark) (Ambion, Inc.). The transcription reaction using MEGAscript was performed as follows. 1  $\mu$ g of template DNA dissolved in ultrapure water, 2  $\mu$ L of T7 10 $\times$  Reaction Buffer, 2  $\mu$ L of T7 ATP Solution (75 mM) (the same recipe for CTP, GTP, and UTP), and 2  $\mu$ L of T7 Enzyme Mix were mixed and adjusted with ultrapure water to the whole amount of 20  $\mu$ L. This reaction solution was reacted at 37° C. for 4 hours to overnight. After the reaction, the solution was supplemented with 1  $\mu$ L of TURBO DNase and incubated at 37° C. for 15 minutes to decompose the template DNA. Each mRNA obtained through the transcription reaction was purified using RNeasy MinElute (trademark) Cleanup Kit (QIAGEN GmbH).

The names of templates and primers used for preparing each RNA will be shown. In the scheme of miRNA EGFP ON switch production, Original EGFP mRNA (SEQ ID NO: 7) was used as a template DNA for 1st PCR. EGFP DNA after 1st PCR was used as a template DNA for 2nd PCR using primers 5' UTR-miRNA156 fwd (5'GGGAGACCACAACGGTTCCCTCTATCTCCTGTGCT-CACTCTCTTCTGTCAAGA AGGAGATATACCAATG-3', SEQ ID NO: 33) and EGFP rev (SEQ ID NO: 3). miRNA156-responsive EGFP DNA after 2nd PCR was used as a template DNA for 3rd PCR using primers T7-stem-loop uni (SEQ ID NO: 10) and EGFP rev (SEQ ID NO: 3).

5' miR156-responsive DsRed Monomer (SEQ ID NO: 34) was also prepared in the same way as above.

In the scheme of this miRNA-responsive DsRed Monomer ON switch production, pDsRed Monomer (Clontech) (SEQ ID NO: 13) was used as a template DNA for 1st PCR using primers DsRed Monomer fwd (SEQ ID NO: 14) and DsRed Monomer rev (SEQ ID NO: 15). DsRed Monomer DNA after 1st PCR was used as a template DNA for 2nd PCR using primers 5' UTR-miRNA156 fwd (SEQ ID NO: 34) and DsRed Monomer rev (SEQ ID NO: 15). miRNA156-responsive DsRed Monomer DNA after 2nd PCR was used as a template DNA for 3rd PCR using primers T7-stem-loop uni (SEQ ID NO: 10) and DsRed Monomer rev (SEQ ID NO: 15).

Moreover, miR156 (5'-UGACAGAAGAGAGUGAGAC-3', SEQ ID NO: 35), an miRNA complementarily binding to each of 5' miR156-responsive EGFP and 5' miR156-responsive DsRed Monomer was purchased from Hokkaido System Science Co., Ltd.

[Translational Regulation Assay Using Cell-Free Expression System of RNA-Responsive Artificial RNA Switch]

2000 nM each RNA-responsive artificial RNA switches thus prepared were supplemented with each miRNA complementarily binding to each RNA-responsive artificial RNA switch, and EGFP and DsRed Monomer proteins were

## 23

expressed in the PURE system and confirmed for their fluorescence intensities using each filter. The ratio of change in fluorescence intensity was plotted against change in the concentration of each miRNA when the fluorescence intensity of each protein obtained without the miRNA addition is defined as 1.

FIG. 21 is a graph of plotting the ratio of change in fluorescence intensity against each concentration of miR164, miR156, or miR163 added to the 5' miR164-responsive EGFP switch. FIG. 22 is a graph of plotting the ratio of change in fluorescence intensity against each concentration of miR156 or miR164 added to the 5' miR156-responsive EGFP switch. FIG. 23 is a graph of plotting the ratio of change in fluorescence intensity against each concentration of miR164 or miR156 added to the 5' miR164-responsive DsRed Monomer switch. FIG. 24 is a graph of plotting the ratio of change in fluorescence intensity against each concentration of miR156 or miR164 added to the 5' miR156-responsive DsRed Monomer switch. As is evident from these results, each switch can specifically recognize only the target miRNA from among miRNAs similar in sequence and length to activate translation. Furthermore, it was revealed that the type of a gene to be translated is independent of a particular sequence and the translational activation of an arbitrary gene can be regulated.

## Example 6

## [Two Different ON Switch RNAs]

Two RNA-responsive artificial RNA switches that switch ON gene expression in response to different miRNAs were prepared and combined to construct the simplest artificial translational system.

The RNA-responsive artificial RNA switches used were 5' miR164-responsive DsRed Monomer and 5' miR156-responsive EGFP prepared in Example 5. miR164 (SEQ ID NO: 29) and miR156 (SEQ ID NO: 39) were used as miRNAs complementarily binding to each RNA-responsive artificial RNA switch.

A mixed solution containing 2000 nM each of two RNA-responsive artificial RNA switches was supplemented with 4000 nM each miRNA. Next, EGFP and DsRed Monomer proteins were expressed in the PURE system and confirmed for their fluorescence intensities using each filter. The ratio of change in fluorescence intensity depending on each added miRNA was plotted when the fluorescence intensity of each protein obtained without the miRNA addition is defined as 1. The results are shown in FIG. 25. As is evident from the graph, the addition of miRNA156 caused the green fluorescence of EGFP while the addition of miRNA164 caused the red fluorescence of DsRed Monomer. Thus, the selective emission of green or red fluorescence could be achieved, demonstrating the successful construction of the artificial translational system.

## Example 7

## [OFF Switch EGFP]

## [Design]

RNA-responsive artificial RNA switches that switch OFF EGFP expression in response to an miRNA were prepared. FIGS. 26 and 27 show the designed RNA-responsive artificial RNA switches, miRNAs specifically binding thereto, and reverse complements of the miRNAs. Moreover, below each RNA-responsive artificial RNA switch, amino acids are shown, which are added to the N terminus of the expressed EGFP by inserting the reverse complement of the miRNA 3'

## 24

to the start codon and 5' to the EGFP gene. The RNA-responsive artificial RNA switch shown in FIG. 26 is intended to cause EGFP expression in the absence of miRNA156 (SEQ ID NO: 35) and repress EGFP expression in response to miRNA156. This mRNA is referred to as an miR156-responsive EGFP OFF switch (SEQ ID NO: 36). The miR156-responsive EGFP OFF switch contains the sequence of the reverse complement (5'-GUGCUCACUCUCUCUGUCA-3', SEQ ID NO: 37) of miRNA156.

The RNA-responsive artificial RNA switch shown in FIG. 27 is intended to cause EGFP expression in the absence of miRNA164 (SEQ ID NO: 29) and repress EGFP expression in response to miRNA164. This mRNA is referred to as an miR164-responsive EGFP OFF switch (SEQ ID NO: 38). The miR164-responsive EGFP OFF switch contains the sequence of the reverse complement (5'-UGCACGUGCCCCUGCUUCUCCA-3', SEQ ID NO: 39) of miRNA164.

## [Production]

All template DNAs for artificial RNA switches were prepared by performing twice or three times PCR using Gradient Master Cycler (Eppendorf). All PCR reactions were performed according to the following protocol using KOD-PLUS-(TOYOBO CO., LTD.). 50  $\mu$ L of PCR reaction solution contained a mixture of 25 ng of template DNA, 1.5  $\mu$ L of 10  $\mu$ M each DNA primers, 5  $\mu$ L of 2 mM dNTPs, 5  $\mu$ L of 10 $\times$ KOD-PLUS-buffer ver. 2, 2  $\mu$ L of 25 mM MgSO<sub>4</sub>, and 1  $\mu$ L of KOD-PLUS-DNA polymerase. Reaction was performed by initially performing incubation at 94 $^{\circ}$  C. for 2 minutes and then 20 cycles each involving 94 $^{\circ}$  C. for 15 seconds, 50 $^{\circ}$  C. for 30 seconds, and 68 $^{\circ}$  C. for 1 minute. After the reaction, the reaction solution was subjected to phenol treatment and ethanol precipitation and dissolved in a non-denaturing dye (30% glycerin, 0.075% xylene cyanol, 0.075% bromophenol blue, 69.85% ultrapure water). The band of interest was separated and excised using low melting point agarose SEAPLAQUE GTG AGAROSE (FMC Corp.). The excised agarose fragment was supplemented with 200  $\mu$ L of TE, then incubated at 65 $^{\circ}$  C. for 30 minutes, and then subjected to 3 phenol treatments, diethyl ether treatment, and ethanol precipitation for DNA purification. The purification product was dissolved in ultrapure water, followed by concentration measurement using DU640 SPECTROPHOTOMETER (Beckman Coulter, Inc.).

Each template DNA thus prepared was used to perform transcription reaction using MEGAscript (trademark) (Ambion, Inc.). The transcription reaction using MEGAscript was performed as follows. 1  $\mu$ g of template DNA dissolved in ultrapure water, 2  $\mu$ L of T7 10 $\times$  Reaction Buffer, 2  $\mu$ L of T7 ATP Solution (75 mM) (the same recipe for CTP, GTP, and UTP), and 2  $\mu$ L of T7 Enzyme Mix were mixed and adjusted with ultrapure water to the whole amount of 20  $\mu$ L. This reaction solution was reacted at 37 $^{\circ}$  C. for 4 hours to overnight. After the reaction, the solution was supplemented with 1  $\mu$ L of TURBO DNase and incubated at 37 $^{\circ}$  C. for 15 minutes to decompose the template DNA. Each mRNA obtained through the transcription reaction was purified using RNeasy MinElute (trademark) Cleanup Kit (QIAGEN GmbH).

In the scheme of miRNA-responsive EGFP OFF switch production, pEGFP (Clontech) (SEQ ID NO: 1) was used as a template DNA for 1st PCR using primers miR156-responsive OFF fwd (5'AAGGAGATATACCAATGGTGCTCACTCTCTCTGTCAGGTGAGCAAGGGCGAG GAG-3', SEQ ID NO: 40) or miR164-responsive OFF fwd (5'AAGGAGATATACCAATGTGCACGTGC-CCTGCTTCTCCAGTGAGCAAGGGCGAG GAG-3', SEQ ID NO: 41) and EGFP rev (SEQ ID NO: 3). EGFP DNA after

1st PCR was used as a template DNA for 2nd PCR using primers Universal primer (SEQ ID NO: 5) and EGFP rev (SEQ ID NO: 3). The miRNA and each primer were purchased from Hokkaido System Science Co., Ltd.

[Evaluation]

The miR156-responsive EGFP OFF switch or the miR164-responsive EGFP OFF switch was supplemented with each concentration of miRNA156 or miRNA164. Their EGFP proteins were expressed in the PURE system and confirmed for their fluorescence intensities. Change in fluorescence ratio was plotted against change in the concentration of each miRNA when the fluorescence intensity obtained without the miRNA addition is defined as 1. The results are shown in the drawings.

FIG. 28 is a graph of plotting the ratio of change in fluorescence intensity against each concentration of miRNA156 or miRNA164 added to 200 nM miR156-responsive EGFP OFF switch. FIG. 29 is a graph of plotting the ratio of change in fluorescence intensity against each concentration of miRNA156 or miRNA164 added to 100 nM miR164-responsive EGFP OFF switch. As is evident from both the graphs, specific translational repression occurred. Moreover, from these results, it was found that even when the reverse complement of the miRNA is inserted immediately downstream of the start codon, the efficiency of expression of EGFP proteins with N-terminally added 7 amino acids is not reduced. This is a dramatic outcome demonstrating that the design of the EGFP OFF switch attained greater success than expected.

[OFF Switch DsRed Monomer]

[Design]

RNA-responsive artificial RNA switches that switch OFF DsRed Monomer expression in response to an miRNA were prepared. FIGS. 30 and 31 show the designed RNA-responsive artificial RNA switches, miRNAs specifically binding thereto, and reverse complements of the miRNAs. Moreover, beneath each RNA-responsive artificial RNA switch, amino acids are shown, which are added to the N terminus of the expressed DsRed Monomer by inserting the reverse complement of the miRNA 3' to the start codon and 5' to the DsRed Monomer gene. The RNA-responsive artificial RNA switch shown in FIG. 30 is intended to cause DsRed Monomer expression in the absence of miRNA156 and repress DsRed Monomer expression in response to miRNA156. This mRNA is referred to as an miR156-responsive DsRed Monomer OFF switch RNA (SEQ ID NO: 42). The RNA-responsive artificial RNA switch shown in FIG. 31 is intended to cause DsRed Monomer expression in the absence of miRNA164 and repress DsRed Monomer expression in response to miRNA164. This mRNA is referred to as an miR164-responsive DsRed Monomer OFF switch RNA (SEQ ID NO: 43).

[Production]

The miR156-responsive DsRed Monomer OFF switch and the miR164-responsive DsRed Monomer OFF switch were produced in the same way as in the OFF switch EGFP.

pDsRed Monomer (Clontech) (SEQ ID NO: 13) was used as a template DNA for 1st PCR using primers miR156-responsive OFF fwd (SEQ ID NO: 40) or miR164-responsive OFF fwd (SEQ ID NO: 41) and DsRed Monomer rev (SEQ ID NO: 16). DsRed Monomer DNA after 1st PCR was used as a template DNA for 2nd PCR using primers Universal primer (SEQ ID NO: 5) and DsRed Monomer rev (SEQ ID NO: 16).

[Evaluation]

200 nM each miR156-responsive DsRed Monomer OFF switch or 200 nM miR164-responsive DsRed Monomer OFF switch was supplemented with each concentration of miRNA156 or miRNA164. Their EGFP proteins were expressed in the PURE system and confirmed for their fluo-

rescence intensities. Change in fluorescence ratio was plotted against change in the concentration of each miRNA when the fluorescence intensity obtained without the miRNA addition is defined as 1. The results are shown in the drawings.

FIG. 32 is a graph of plotting the ratio of change in fluorescence intensity against each concentration of miRNA156 or miRNA164 added to 200 nM miR156-responsive DsRed Monomer OFF switch. FIG. 33 is a graph of plotting the ratio of change in fluorescence intensity against each concentration of miRNA156 or miRNA164 added to 200 nM miR164-responsive DsRed Monomer OFF switch. As is evident from both the graphs, specific translational repression occurred. In this case as well, the reverse complement of the miRNA inserted immediately downstream of the start codon has a little influence on the efficiency of DsRed Monomer expression, as in EGFP, demonstrating that the OFF switch was successfully designed efficiently.

#### Example 8

[Artificial Translational System Using Different Switches Responding to the Same Small RNA]

[From Green to Red]

An artificial translational system using different switches responding to the same small RNA was evaluated. An miR164-responsive EGFP OFF switch (FIG. 27) that regulates EGFP expression in an ON-to-OFF manner in response to miR164 was prepared according to Example 7. An miR164-responsive DsRed Monomer ON switch (SEQ ID NO: 19) that regulates DsRed Monomer expression in an OFF-to-ON manner in response to miR164 was prepared according to Example 1.

A mixed solution of 100 nM miR164-responsive EGFP OFF switch and 2000 nM miR164-responsive DsRed Monomer ON switch was supplemented with each concentration of miR156 or miR164, and EGFP and DsRed Monomer proteins were expressed in the PURE system and confirmed for their fluorescence intensities using each filter. The ratio of change in fluorescence intensity was plotted against change in the concentration of each miRNA when the fluorescence intensity of each protein obtained without the miRNA addition is defined as 1. The results are shown in FIG. 34. In the graph of FIG. 34, the left scales relate to miR156 EGFP, miR156 DsRed, and miR164 DsRed, and the right scales relate to miR164 EGFP. In this context, miR156 EGFP represents the fluorescence ratio of EGFP obtained by the addition of miR156; miR156 DsRed represents the fluorescence ratio of DsRed obtained by the addition of miR156; miR164 EGFP represents the fluorescence ratio of EGFP obtained by the addition of miR164; and miR164 DsRed represents the fluorescence ratio of DsRed obtained by the addition of miR164. miR164-specific change from green to red colors could be confirmed, demonstrating that the artificial translational system was successfully constructed. Moreover, the absence of change in fluorescence caused by miRNA156 was used as a control.

[From Red to Green]

Other artificial translational systems using different switches responding to the same small RNA were evaluated.

A 5' miR156-responsive EGFP ON switch that regulates EGFP expression in an OFF-to-ON manner in response to miR156 was prepared according to Example 5. On the other hand, an miR156-responsive DsRed Monomer OFF switch (FIG. 30) that regulates DsRed Monomer expression in an ON-to-OFF manner in response to miR156 was prepared according to Example 7.

A mixed solution of 2000 nM 5' miR156-responsive EGFP ON switch and 500 nM miR156-responsive DsRed Monomer OFF switch was supplemented with each concentration of miR156 or miR164, and EGFP and DsRed Monomer proteins were expressed in the PURE system and confirmed for their fluorescence intensities using each filter. The ratio of change in fluorescence intensity was plotted against change in the concentration of each miRNA when the fluorescence intensity of each protein obtained without the miRNA addition is defined as 1. The results are shown in FIG. 35. In the graph of FIG. 35, the left scales relate to miR156 EGFP, miR164 EGFP, and miR164 DsRed, and the right scales relate to miR156 DsRed. miR156-specific change from red to green colors could be confirmed, demonstrating that the artificial translational system was successfully constructed. Moreover, the absence of change in fluorescence caused by miRNA164 was used as a control.

A 5' miR164-responsive EGFP ON switch that regulates EGFP expression in an OFF-to-ON manner in response to miR164 was prepared according to Example 1. On the other hand, a miR164-responsive DsRed Monomer OFF switch (FIG. 31) that regulates DsRed Monomer expression in an ON-to-OFF manner in response to miR164 was prepared according to Example 7.

A mixed solution of 2000 nM 5' miR164-responsive EGFP ON switch and 500 nM miR164-responsive DsRed Monomer OFF switch was supplemented with each concentration of miR156 or miR164, and EGFP and DsRed Monomer proteins were expressed in the PURE system and confirmed for their fluorescence intensities using each filter. The ratio of change in fluorescence intensity was plotted against change in the concentration of each miRNA when the fluorescence intensity of each protein obtained without the miRNA addition is defined as 1. The results are shown in FIG. 36. In the graph of FIG. 36, the left scales relate to miR156 EGFP, miR164 EGFP, and miR156 DsRed, and the right scales relate to miR164 DsRed. miR164-specific change from red to green colors could be confirmed, demonstrating that the artificial translational system was successfully constructed. Moreover, the absence of change in fluorescence caused by miRNA156 was used as a control.

#### Example 9

[Double ON Switch]

[Preparation of RNA-Responsive Artificial RNA (miRNA159a-Responsive EGFP on Switch)]

An RNA-responsive artificial RNA (miRNA159a-responsive EGFP ON switch) was prepared in the same way as in Example 1. FIG. 37 shows miRNA159a (5'-UUUGGA-UUGAAGGGAGCUCUA-3', SEQ ID NO: 44), its complementary strand (5'-UAGAGCUCCUUCUAUCCAAA-3', SEQ ID NO: 45), and the secondary structure of a double ON switch mRNA (SEQ ID NO: 46) specifically reacting with miRNA159a.

[Preparation of RNA-Responsive Artificial RNA (miRNA163-Responsive EGFP ON Switch)]

An RNA-responsive artificial RNA (miRNA163-responsive EGFP ON switch) was prepared in the same way as in Example 1. FIG. 38 shows miRNA163 (SEQ ID NO: 28), its complementary strand (5'-AUCGAAGUCCAAGUCCU-

CUUCAA-3', SEQ ID NO: 47), and the secondary structure of a double ON switch mRNA (SEQ ID NO: 48) specifically reacting with miRNA163.

[Translational Regulation Assay Using Cell-Free Expression System of RNA-Responsive Artificial RNA Switch]

A cell-free expression system PURE system was used for confirming the translational regulations of these two RNA-responsive artificial RNA switches. The PURE system is as described in Example 2.

[Assay on miRNA159a-Responsive EGFP ON Switch]

Five solutions each containing a mixture of 1  $\mu$ L of 20  $\mu$ M miRNA159a-responsive EGFP, 1  $\mu$ L of ultrapure water, 5  $\mu$ L of Solution A, and 2  $\mu$ L of Solution B were prepared and supplemented with 1  $\mu$ L each of 40  $\mu$ M, 20  $\mu$ M, 10  $\mu$ M, 5  $\mu$ M, and 0  $\mu$ M synthesized miRNA159a (SEQ ID NO: 44), respectively, to adjust the whole amount of 10  $\mu$ L. The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with ultrapure water to 200  $\mu$ L and measured at an excitation wavelength of 485 nm and an absorption wavelength of 535 nm using infinite F200 (manufactured by TECAN Trading AG) (FIG. 39). For negative controls, five solutions each containing a mixture of 1  $\mu$ L of 20  $\mu$ M miRNA159a-responsive EGFP, 1  $\mu$ L of ultrapure water, 5  $\mu$ L of Solution A, and 2  $\mu$ L of Solution B were prepared and supplemented with 1  $\mu$ L each of 40  $\mu$ M, 20  $\mu$ M, 10  $\mu$ M, 5  $\mu$ M, and 0  $\mu$ M synthesized miRNA163 (Hokkaido System Science Co., Ltd., SEQ ID NO: 28), respectively, to adjust the whole amount of 10  $\mu$ L. The solutions were reacted at 37° C. for 75 minutes. After the reaction, each solution was adjusted with ultrapure water to 200  $\mu$ L and measured at an excitation wavelength of 485 nm and an absorption wavelength of 535 nm using infinite F200 (TECAN Trading AG) (FIG. 39). This assay demonstrated that this RNA-responsive artificial RNA switch (miRNA159a-responsive EGFP) specifically reacts with miRNA159a to perform OFF-to-ON translational regulation.

[Assay on miRNA163-Responsive EGFP ON Switch]

An miRNA163-responsive EGFP ON switch (SEQ ID NO: 48) was assayed in the same way as in the miRNA159a-responsive EGFP. For negative controls, an miRNA163-responsive EGFP ON switch was supplemented with miRNA159a for use. The concentration of the miRNA163-responsive EGFP switch was set to 1  $\mu$ M. The measurement results are shown in FIG. 40. This assay demonstrated that the miRNA163-responsive EGFP ON switch specifically reacts with miRNA163 to perform OFF-to-ON translational regulation.

#### INDUSTRIAL APPLICABILITY

In applications, the present invention can function as biosensors or artificial genetic circuits that can regulate the expression of downstream signal proteins (e.g., fluorescent or luminescent proteins) in response to the expression of an arbitrary RNA. By intracellular introduction of this artificial RNA, the present invention can be developed into systems that detect cells expressing a particular RNA (miRNA, etc.) without destroying the cells, or into techniques of regulating the fate of cells.

Moreover, an intraliposomal genetic network can be constructed by encapsulating the artificial RNA together with a cell-free translational system into liposomes.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 59

<210> SEQ ID NO 1  
 <211> LENGTH: 720  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 1

```
atggtgagca agggcgagga gctgttcacc ggggtggtgc ccatcctggt cgagctggac    60
ggcgcagtaa acggccacaa gttcagcgtg tccggcgagg gcgagggcga tgccacctac    120
ggcaagctga ccctgaagtt catctgcacc accgcaagc tgcccgtgcc ctggcccacc    180
ctcgtgacca cctcgaccta cggcgtgcag tgcttcagcc gctaccccga ccacatgaag    240
cagcagcact tcttcaagtc cgccatgcc gaaggtacg tccaggagcg caccatcttc    300
ttcaaggacg acggcaacta caagaccgc gccgaggtga agttcgaggg cgacaccctg    360
gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg acggcaacat cctggggcac    420
aagctggagt acaactacaa cagccacaac gtctatatca tggccgacaa gcagaagaac    480
ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt gcagctcgcc    540
gaccactacc agcagaacac ccccatcgcc gacggccccg tgctgctgcc cgacaaccac    600
taactgagca cccagtcgcg cctgagcaaa gaccccaacg agaagcgcga tcacatggtc    660
ctgctggagt tcgtgaccgc cgccgggatc actctcgcca tggacgagct gtacaagtaa    720
```

<210> SEQ ID NO 2  
 <211> LENGTH: 32  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 2

```
aaggagatat accaatggtg agcaagggcg ag    32
```

<210> SEQ ID NO 3  
 <211> LENGTH: 27  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 3

```
tattcattac cggcggcgg tcacgaa    27
```

<210> SEQ ID NO 4  
 <211> LENGTH: 710  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 4

```
aaggagatat accaatggtg agcaagggcg aggagctggt caccgggggtg gtgcccattcc    60
tggtcgagct ggacggcgac gtaaacggcc acaagttcag cgtgtccggc gagggcgagg    120
gcgatgccac ctacggcaag ctgacctga agttcatctg caccaccggc aagctgcccc    180
tgccctggcc caccctcgtg accacctga cctacggcgt gcagtgttc agccgetacc    240
```

-continued

---

cgcaccacat gaagcagcac gacttcttca agtccgccat gcccgaaaggc tacgtccagg	300
agcgcacccat cttcttcaag gacgacggca actacaagac ccgcgccgag gtgaagtctg	360
agggcgacac cctggtgaac cgcacgcagc tgaagggcat cgacttcaag gaggacggca	420
acatcctggg gcacaagctg gagtacaact acaacagcca caacgtctat atcatggccg	480
acaagcagaa gaacggcatc aagggtgaact tcaagatccg ccacaacatc gaggacggca	540
gcgtgcagct cgccgaccac taccagcaga acacccccat cgccgacggc cccgtgctgc	600
tgcccgacaa ccactacctg agcaccagc cgcacctgag caaagacccc aacgagaagc	660
gcgatccatc ggtcctgctg gagttcgtga ccgcccggcg gtaatgaata	710

<210> SEQ ID NO 5  
 <211> LENGTH: 85  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 5

gaaattaata cgactcacta tagggagacc acaacggttt ccctctagaa ataattttgt	60
ttaactttaa gaaggagata tacca	85

<210> SEQ ID NO 6  
 <211> LENGTH: 781  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 6

gaaattaata cgactcacta tagggagacc acaacggttt ccctctagaa ataattttgt	60
ttaactttaa gaaggagata taccaatggt gagcaaggc gaggagctgt tcaccggggt	120
ggtgcccac cctggtcagc tggacggcga cgtaaacggc cacaagttca gcgtgtccgg	180
cgagggcgag ggcgatgcca cctacggcaa gctgaccctg aagttcatct gcaccaccg	240
caagctgccc gtgcccctggc ccaccctcgt gaccaccctg acctacggcg tgcagtgctt	300
cagccgctac cccgaccaca tgaagcagca cgacttcttc aagtcgccca tgcccgaagg	360
ctacgtccag gagcgacca tcttcttcaa ggacgacggc aactacaaga cccgcgccga	420
ggtgaagttc gagggcgaca ccttgggtgaa ccgcatcgag ctgaagggca tcgacttcaa	480
ggaggacggc aacatcctgg ggcacaagct ggagtacaac tacaacagcc acaacgtcta	540
tatcatggcc gacaagcaga agaacggcat caaggtgaac ttcaagatcc gccacaacat	600
cgaggacggc agcgtgcagc tcgcccacca ctaccagcag aacacccccca tcgccgacgg	660
ccccgtgctg ctgcccgaca accactacct gagcaccag tccgcccctga gcaaagacc	720
caacgagaag cgcgatcaca tggctcctgct ggagttcgtg accgcccggc ggtaatgaat	780
a	781

<210> SEQ ID NO 7  
 <211> LENGTH: 759  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 7

gggagaccac aacgguuucc cucuagaaau aauuuuuuuu aacuuuaaga aggagauaua	60
-------------------------------------------------------------------	----

-continued

---

```

ccaauagguga gcaagggcgga ggagcuguuc accgggguggg ugcccauccu ggucgagcug 120
gacggcgacg uaaacggcca caaguucagc gugucggcg agggcgaggg cgaugccacc 180
uacggcaagc ugaccugaa guucaucugc accaccggca agcugcccgu gccucggccc 240
accucguga ccaccugac cuacggcgug cagugcuua gccgcuacc cgaccacaug 300
aagcagcacg acuucucaa guccgccaug cccgaaggcu acguccagga gcgcaccauc 360
uuucucaagg acgacggcaa cuacaagacc cgcgcggagg ugaaguucga gggcgacacc 420
cuggugaacc gcaucgagcu gaagggcauc gacuucaagg aggacggcaa cauccugggg 480
cacaagcugg aguacaacua caacagccac aacgucuaua ucauggccga caagcagaag 540
aacggcauca aggugaacuu caagauccgc cacaacaucg aggacggcag cgugcagcuc 600
gccgaccacu accagcagaa ccccccauc gccgacggcc cggugcugcu gcccgacaac 660
cacuaccuga gcaccaguc cggccugagc aaagaccca acgagaagcg cgaucacaug 720
guccugcugg aguucgugac cgcgcggggg uaaugaaua 759

```

```

<210> SEQ ID NO 8
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 8

```

```

gggagaccac aacggtttcc ctctatctcc ttgcacgtgc cctgcttctc caagaaggag 60
atataccaat g 71

```

```

<210> SEQ ID NO 9
<211> LENGTH: 764
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 9

```

```

gggagaccac aacggtttcc ctctatctcc ttgcacgtgc cctgcttctc caagaaggag 60
atataccaat ggtgagcaag ggcgaggagc tgttcaccgg ggtggtgccc atcctggtcg 120
agctggacgg cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc gagggcgatg 180
ccacctacgg caagctgacc ctgaagtcca tctgcaccac cggcaagctg cccgtgccct 240
ggcccacct cgtgaccacc ctgacctacg gcgtgcagtg cttcagccgc taccaccgacc 300
acatgaagca gcacgacttc ttcaagtccg ccatgcccga aggctacgtc caggagcgca 360
ccatcttctt caaggacgac ggcaactaca agaccggcgc cgagggtgaag ttcgagggcg 420
acaccctggt gaaccgcatc gagctgaagg gcatcgactt caaggaggac ggcaacatcc 480
tggggcacia gctggagtac aactacaaca gccacaact ctatatcatg gccgacaagc 540
agaagaacgg catcaagggt aacttcaaga tccgccacia catcgaggac ggcagcgtgc 600
agctcgccga cactaccag cagaacaccc ccatcgccga cggccccgtg ctgctgcccg 660
acaaccacta cctgagcacc cagtccgccc tgagcaaaga cccaacgag aagcgcgatc 720
acatggtcct gctggagttc gtgaccgccc cgggtaatg aata 764

```

```

<210> SEQ ID NO 10
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

```

-continued

---

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 10

gaaattaata cgactcacta tagggagacc acaacggttt cc 42

<210> SEQ ID NO 11

<211> LENGTH: 786

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 11

gaaattaata cgactcacta tagggagacc acaacggttt ccctctatct ccttgcaagt 60

gccttgcttc tccaagaagg agatatacca atggtgagca agggcgagga gctgttcacc 120

gggtggtgc ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg 180

tcggcgaggg gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc 240

accggcaagc tgcccgtgcc ctggcccacc ctctgacca ccctgaccta cggcgtgcag 300

tgcttcagcc gctacccoga ccacatgaag cagcagcact tcttcaagtc cgccatgccc 360

gaaggctacg tccaggagcg caccatcttc ttcaaggacg acggcaacta caagaccgcg 420

gccgaggtga agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac 480

ttcaaggagg acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac 540

gtctatatca tggccgacaa gcagaagaac ggcacaaagg tgaacttcaa gatccgccac 600

aacatcgagg acggcagcgt gcagctcgcc gaccactacc agcagaacac ccccatcgcc 660

gacggccccg tgctgctgcc cgacaaccac tacctgagca cccagtcgcg cctgagcaaa 720

gaccccaacg agaagcgcga tcacatggtc ctgctggagt tcgtgaccgc cgccgggtaa 780

tgaata 786

<210> SEQ ID NO 12

<211> LENGTH: 764

<212> TYPE: RNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 12

gggagaccac aacgguuucc cucuaucucc uugcagcugc ccugcuucuc caagaaggag 60

auauaccaau ggugagcaag ggcgaggagc uguuaccggg gguggugccc auccuggucg 120

agcuggacgg cgacguaaac ggccacaagu ucagcguguc cggcgagggg gagggcgau 180

ccaccuacgg caagcugacc cugaaguuca ucugcaccac cggcaagcug cccgugcccu 240

ggcccaccuu cgugaccacc cugaccuacg gcgugcagug cuucagccgc uaccccagcc 300

acaugaagca gcacgacuuc uucaaguccg ccaugcccga aggcuaagcug caggagcgca 360

ccaucuucuu caaggagcag ggcaacuaca agaccgcgc cgaggugaag uucgagggcg 420

acaccuggu gaaccgcauc gagcugaagg gcaucgacuu caaggaggac ggcaacauc 480

uggggcacia gcuggaguac aacuacaaca gccacaacgu cuauaucaug gccgacaagc 540

agaagaacgg caucaaggug aacuucaaga uccgccacaa caucgaggac ggcagcgugc 600

agcucgcccga ccacuaccag cagaacacc ccaucgcccga cggccccgug cugcugcccg 660

acaaccacua ccugagcacc caguccgccc ugagcaaaaga cccaacagag aagcgcgau 720

acaugguccu gcuggaguuc gugaccgccc cggguuaug aaau 764

-continued

---

```

<210> SEQ ID NO 13
<211> LENGTH: 678
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 13
atggacaaca ccgaggacgt catcaaggag ttcattgcagt tcaaggtgcg catggagggc   60
tccgtgaacg gccactactt cgagatcgag ggcgagggcg agggcaagcc ctacgagggc   120
accagaccg ccaagctgca ggtgaccaag ggcggcccc tgccttcgc ctgggacatc   180
ctgtcccccc agttccagta cggtccaag gcctacgtga agcaccccgc cgacatcccc   240
gactacatga agctgtcctt ccccgagggc ttcacctggg agcgctccat gaacttcgag   300
gacggcggcg tggtaggagt gcagcaggac tctcctctgc aggacggcac ctctcatctac   360
aaggtgaagt tcaagggcgt gaacttcccc gccgaaggcc ccgtaatgca gaagaagact   420
gccggctggg agcctccac cgagaagctg taccctcagg acggcgtgct gaagggcgag   480
atctcccacg ccctgaagct gaaggacggc gccactaca cctgcgactt caagaccgtg   540
tacaaggcca agaagcccgt gcagctgcc gccaaacct acgtggactc caagctggac   600
atcaccaacc acaacgagga ctacaccgtg gtggagcagt acgagcacgc cgaggcccgc   660
cactccggct ccagtag                                     678

```

```

<210> SEQ ID NO 14
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 14
aaggagatat accaatggac aacaccgagg acg                                     33

```

```

<210> SEQ ID NO 15
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 15
tattcattac tactgggagc cggagtgg                                     28

```

```

<210> SEQ ID NO 16
<211> LENGTH: 701
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 16
aaggagatat accaatggac aacaccgagg acgtcatcaa ggagtcatg cagttcaagg   60
tgcgcatgga gggctccgtg aacggccact acttcgagat cgagggcgag ggcgagggca   120
agccctacga gggcaccag accgccaagc tgcaggtgac caagggcggc ccctgcct   180
tcgcctggga catcctgtcc ccccagttcc agtacggctc caaggcctac gtgaagcacc   240
ccgcccagat ccccgactac atgaagctgt ccttccccga gggcttcacc tgggagcgt   300
ccatgaactt cgaggacggc ggcgtggtgg aggtgcagca ggactcctcc ctgcaggacg   360

```

-continued

---

gcaccttcat ctacaaggtg aagttcaagg gcgtaactt ccccgccgac ggccccgtaa	420
tgcagaagaa gactgccggc tgggagccct ccaccgagaa gctgtacccc caggacggcg	480
tgctgaaggg cgagatctcc cacgccctga agctgaagga cggcggccac tacacctgcg	540
acttcaagac cgtgtacaag gccaaagaac ccgtcagct gcccggaac cactactggtg	600
actccaagct ggacatcacc aaccacaacg aggactacac cgtgggtggag cagtacgagc	660
acgccgaggc ccgccactcc ggctcccagt agtaatgaat a	701

<210> SEQ ID NO 17  
 <211> LENGTH: 755  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 17

gggagaccac aacggtttcc ctctatctcc ttgcaogtgc cctgcttctc caagaaggag	60
atataccaat ggacaacacc gaggacgtca tcaaggagtt catgcagtcc aagggtgcgca	120
tggagggctc cgtgaacggc cactacttcg agatcgaggg cgagggcgag ggcaagccct	180
acgagggcac ccagaccgcc aagctgcagg tgaccaaggg cggccccctg cccttcgctc	240
gggacatcct gtccccccag ttccagtagc gctccaaggc ctacgtgaag cccccgccc	300
acatccccga ctacatgaag ctgtccttcc ccgagggett cacctgggag cgetccatga	360
acttcgagga cggcggcgtg gtggaggtgc agcaggactc ctccctgcag gacggcacct	420
tcatctacaa ggtgaagtcc aagggcgtga acttccccgc cgacggcccc gtaatgcaga	480
agaagactgc cggctgggag cctccaccg agaagctgta cccccaggac ggcggtgctga	540
agggcgagat ctcccacgcc ctgaagctga aggacggcgg ccactacacc tgcgacttca	600
agaccgtgta caaggccaag aagcccgtgc agctgcccgg caaccactac gtggactcca	660
agctggacat caccaaccac aacgaggact acaccgtggt ggagcagtac gagcacgccc	720
agggccgcca ctccggctcc cagtagtaat gaata	755

<210> SEQ ID NO 18  
 <211> LENGTH: 777  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 18

gaaattaata cgactcacta tagggagacc acaacggttt ccctctatct cctgcaactg	60
gccctgcttc tccaagaagg agatatacca atggacaaca ccgaggacgt catcaaggag	120
ttcatgcagt tcaaggtgcg catggagggc tccgtgaacg gccactactt cgagatcgag	180
ggcgagggcg agggcaagcc ctacgagggc acccagaccg ccaagctgca ggtgaccaag	240
ggcggccccc tgccccttcg ctgggacatc ctgtcccccc agttccagta cggctccaag	300
gcctacgtga agcaccctgc cgacatcccc gactacatga agctgtcctt ccccaggggc	360
ttcacctggg agcgtccat gaacttcgag gacggcggcg tgggtggaggt gcagcaggac	420
tcctccctgc aggacggcac ctctcatctac aaggtgaagt tcaagggcgt gaacttcccc	480
gccgacggcc ccgtaatgca gaagaagact gccggctggg agccctccac cgagaagctg	540
tacccccagg acggcgtgct gaagggcgag atctcccacg ccctgaagct gaaggacggc	600
ggccactaca cctgcgactt caagaccgtg tacaaggcca agaagcccgt gcagctgccc	660

-continued

---

 ggcaaccact acgtggactc caagctggac atcaccaacc acaacgagga ctacaccgtg 720

gtggagcagt acgagcacgc cgaggcccgc cactccggct cccagtagta atgaata 777

&lt;210&gt; SEQ ID NO 19

&lt;211&gt; LENGTH: 755

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 19

gggagaccac aacgguuucc cucuauucc uugcacgugc ccugcuucuc caagaaggag 60

auauaccaau ggacaacacc gaggacguca ucaaggaguu caugcaguuc aaggugcgca 120

uggagggcuc cgugaacggc cacuacuucg agaucgaggg cgagggcgag ggcaagccu 180

acgagggcac ccagaccgcc aagcugcagg ugaccaagg gggccccug cccuucgccu 240

gggacauccu guccccccag uuccaguacg gcuccaaggc cuacgugaag caccgcccg 300

acaucgccga cuacaugaag cuguccuucc cggagggcuu caccugggag cgcuccauga 360

acuucgagga cggcgggcug guggaggugc agcaggacuc cuccugcag gacggcaccu 420

ucaucucaa ggugaaguuc aagggcguga acuuccccgc cgacggcccc guaaugcaga 480

agaagacugc cggcugggag cccuccaccg agaagcugua ccccaggac ggcgugcuga 540

agggcgagau cucccacgcc cugaagcuga aggacggcgg ccacuacacc ugcgacuca 600

agaccgugua caaggccaag aagcccugc agcugcccgg caaccacuac guggacucca 660

agcuggacau caccaaccac aacgaggacu acaccguggu ggagcaguac gagcacgccg 720

aggcccgcca cuccggcucc caguaguaau gaaua 755

&lt;210&gt; SEQ ID NO 20

&lt;211&gt; LENGTH: 71

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 20

gggagaccac aacggtttcc ctctatctcc tgatattgac acggctcaat caagaaggag 60

atataccaat g 71

&lt;210&gt; SEQ ID NO 21

&lt;211&gt; LENGTH: 764

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 21

gggagaccac aacggtttcc ctctatctcc tgatattgac acggctcaat caagaaggag 60

atataccaat ggtgagcaag ggcgaggagc tgttcaccgg ggtggtgccc atcctggtcg 120

agctggacgg cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc gagggcgatg 180

ccacctacgg caagetgacc ctgaagtcca tctgcaccac cggcaagctg cccgtgccct 240

ggccccacct cgtgaccacc ctgacctacg gcgtgcagtg ctccagccgc taccgccacc 300

acatgaagca gcacgacttc ttcaagtccg ccatgcccga aggctacgtc caggagcgca 360

ccatcttctt caaggacgac ggcaactaca agaccgccgc cgaggtgaag ttcgagggcg 420

acacctggt gaaccgcac gagctgaagg gcatcgactt caaggaggac ggcaacatcc 480

-continued

---

tggggcacia gctggagtac aactacaaca gccacaacgt ctatatcatg gccgacaagc	540
agaagaacgg catcaaggtg aacttcaaga tccgccacaa catcgaggac ggcagegtgc	600
agctcgccga ccaactaccag cagaacaccc ccactgccga cggccccgtg ctgetgccc	660
acaaccacta cctgagcacc cagtccgcc tgagcaaaga cccaacgag aagcgcgatc	720
acatggtcct gctggagtgc gtgaccgcc cgggtaatg aata	764

<210> SEQ ID NO 22  
 <211> LENGTH: 786  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 22

gaaattaata cgactcacta tagggagacc acaacggttt ccctctatct cctgatattg	60
acacggctca atcaagaagg agatatacca atggtgagca agggcgagga gctgttcacc	120
ggggtggtgc ccactcctgt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg	180
tccggcgagg gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc	240
accggcaagc tgcccgtgcc ctggcccacc ctctgacca ccctgaccta cggcgtgcag	300
tgcttcagcc gctaccccga ccacatgaag cagcacgact tctcaagtc cgccatgcc	360
gaaggctacg tccaggagcg caccatcttc ttcaaggacg acggcaacta caagaccgc	420
gcccaggtga agttcgaggg cgacacctg gtgaaccgca tctgagctgaa gggcatcgac	480
ttcaaggagg acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac	540
gtctatatca tggccgacaa gcagaagaac ggcatcaagg tgaacttcaa gatccgccac	600
aacatcgagg acggcagcgt gcagctgcc gacctacc agcagaacac cccatcgcc	660
gacggccccg tgctgctgcc cgacaaccac tacctgagca ccagtcgcg cctgagcaaa	720
gacccaacg agaagcgcga tcacatggtc ctgctggagt tctgaccgc cggcgggtaa	780
tgaata	786

<210> SEQ ID NO 23  
 <211> LENGTH: 764  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 23

gggagaccac aacgguuucc cucuauucc ugauauugac acggcucaau caagaaggag	60
auauaccaau ggugagcaag ggcgaggagc uguuacccgg gguggugccc auccuggucg	120
agcuggacgg cgacguaac gccacaagu ucagcguguc cggcgagggc gagggcgaug	180
ccaccuacgg caagcugacc cugaaguca ucugcaccac cggcaagcug cccgugcccu	240
ggcccacccu cgugaccacc cugaccuacg gcgugcagug cuucagccgc uaccccgacc	300
acaugaagca gcacgacuuc uucaaguccg ccaugcccga aggcucaguc caggagcgca	360
ccaucuuuu caaggacgac ggcaacuaca agaccgcgc cgaggugaag uucgagggcg	420
acaccuggu gaaccgcauc gagcugaagg gcaucgacu caaggaggac ggcaacauc	480
uggggcacia gcuggaguac aacuacaaca gccacaacgu cuauauaug gccgacaagc	540
agaagaacgg caucaaggug aacuucaaga uccgccacaa caucgaggac ggcagcgugc	600
agcucgccga ccacuaccag cagaacaccc ccaucgcga cggccccgug cugcugccc	660

-continued

---

```

acaaccacua ccugagcacc caguccgcc ugagcaaaga cccaacgag aagcgcgau 720
acaugguccu gcuggaguuc gugaccgcc cggguaaug auaa 764

```

```

<210> SEQ ID NO 24
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 24

```

```

gggagaccac aacggtttcc ctctatctcc tgatattggc gggctcaat caagaaggag 60
atataccaat g 71

```

```

<210> SEQ ID NO 25
<211> LENGTH: 764
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 25

```

```

gggagaccac aacggtttcc ctctatctcc tgatattggc gggctcaat caagaaggag 60
atataccaat ggtgagcaag ggcgaggagc tgttcaccgg ggtggtgcc atcctggtcg 120
agctggacgg cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc gagggcgatg 180
ccacctacgg caagctgacc ctgaagtcca tctgcaccac cggcaagctg cccgtgccct 240
ggcccacct cgtgaccacc ctgacctacg gcgtgcagtg cttcagccgc taccaccgacc 300
acatgaagca gcacgacttc ttcaagtccg ccatgccga aggctacgtc caggagcgca 360
ccatcttctt caaggacgac ggcaactaca agaccgccgc cgaggtgaag ttcgagggcg 420
acacctggt gaaccgcatc gagctgaagg gcatcgactt caaggaggac ggcaacatcc 480
tggggcacaa gctggagtac aactacaaca gccacaacgt ctatatcatg gccgacaagc 540
agaagaacgg catcaagggt aacttcaaga tccgccacaa catcgaggac ggcagcgtgc 600
agctcgccga ccaactaccg cagaacaccc ccatcgccga cggccccgtg ctgctgccc 660
acaaccacta cctgagcacc cagtccgcc tgagcaaaga cccaacgag aagcgcgatc 720
acatggtcct gctggagtcc gtgaccgcc cgggtaatg aata 764

```

```

<210> SEQ ID NO 26
<211> LENGTH: 786
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 26

```

```

gaaattaata cgactcacta tagggagacc acaacggttt ccctctatct cctgatattg 60
gcgcggtcta atcaagaagg agatatacca atggtgagca agggcgagga gctgttcacc 120
ggggtggtgc ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg 180
tccggcgagg gcgagggcga tggcacctac ggcaagctga ccctgaagtt catctgcacc 240
accggcaagc tgcccgtgcc ctggcccacc ctcgtgacca ccctgacctc cggcgtgcag 300
tgcttcagcc gctaccccga ccacatgaag cagcagcact tcttcaagtc cgccatgccc 360
gaaggctacg tccaggagcg caccatcttc ttcaaggacg acggcaacta caagaccgcg 420
gccgaggtga agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac 480

```

-continued

---

ttcaaggagg acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac	540
gtctatatca tggcgcacaa gcagaagaac ggcacaaagg tgaacttcaa gatccgccac	600
aacatcgagg acggcagcgt gcagctcgcc gaccactacc agcagaacac ccccatcgcc	660
gacggccccg tgctgctgcc cgacaaccac tacctgagca ccagtcgcg cctgagcaaa	720
gaccccaacg agaagcgcga tcacatggtc ctgctggagt tcgtgacgc gcgcgggtaa	780
tgaata	786

<210> SEQ ID NO 27  
 <211> LENGTH: 764  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 27

gggagaccac aacgguuucc cucuaucucc ugauauuggc gcggcucaau caagaaggag	60
auauaccaau ggugagcaag ggcgaggagc uguucaccgg gguggugccc auccuggucg	120
agcuggacgg cgacguaaac ggcacaagu ucagcguguc cggcgagggc gagggcgau	180
ccaccuacgg caagcugacc cugaaguca ucugcaccac cggcaagcug cccgugccu	240
ggcccacccu cgugaccacc cugaccuacg gcgugcagug cuucagcgc uaccccgacc	300
acaugaagca gcacgacuuc uucaaguccg ccaugcccga aggcuaugc caggagcgca	360
ccaucuucu caaggacgac ggcaacuaca agaccgcgc cgaggugaag uucgagggcg	420
acaccuggu gaaccgcauc gagcugaagg gcaucgacuu caaggaggac ggcaacauc	480
uggggcacaa gcuggaguac aacuacaaca gccacaacgu cuauaucaug gccgacaagc	540
agaagaacgg caucaaggug aacuucaaga uccgccacaa caucgaggac ggcagcgugc	600
agcucgccga ccacuaccag cagaacaccc ccaucgccga cggccccgug cugcugccc	660
acaaccacua ccugagcacc caguccgcc ugagcaaaga cccaacgag aagcgcgauc	720
acaugguccu gcuggaguuc gugaccgcc cggguuaug auaa	764

<210> SEQ ID NO 28  
 <211> LENGTH: 24  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 28

uugaagagga cuuggaacuu cgau	24
----------------------------	----

<210> SEQ ID NO 29  
 <211> LENGTH: 21  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 29

uggagaagca gggcacgugc a	21
-------------------------	----

<210> SEQ ID NO 30  
 <211> LENGTH: 21  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

-continued

&lt;400&gt; SEQUENCE: 30

ugauugagcc gugucaauau c 21

&lt;210&gt; SEQ ID NO 31

&lt;211&gt; LENGTH: 21

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 31

ugauugagcc ggcaccauau c 21

&lt;210&gt; SEQ ID NO 32

&lt;211&gt; LENGTH: 763

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 32

gggagaccac aacgguuucc cucuauucc ugugcucacu cucuucuguc aagaaggaga 60

uauaccaaug gugagcaagg gcgaggagcu guucaccggg guggugccca uccuggucca 120

gcuggacggc gacguaaaacg gccacaaguu cagcgugucc ggcgaggggc agggcgaucc 180

caccuacggc aagcugaccc ugaaguucac cugcaccacc ggcaagcugc ccgugcccug 240

gcccaccucc gugaccacc ugaaccuacgg cgugcagugc uucagccgcu accccgacca 300

caugaagcag cacgacuucu ucaaguccgc caugcccgaagg ggcuaacgucc aggagcgcac 360

caucuucucc aaggacgacg gcaacuacaa gaccgcgccc gaggugaagu ucgaggggca 420

caccugggug aaccgcaucg agcugaaggc caucgacuuc aaggaggacg gcaacaucuu 480

ggggcacaag cuggaguaca acuacaacag ccacaacguc uauaucaugg ccgacaagca 540

gaagaacggc aucaagguga acuucaagau ccgccacaac aucgaggacg gcagcgugca 600

gcucgccgac cacuaccagc agaacacccc caucgccgac ggccccgugc ugcugcccga 660

caaccacuac cugagcacc aguccgccc gagcaaagac cccaacgaga agcgcgauca 720

caugguccug cuggaguucg ugaccgccc cggguuauga aua 763

&lt;210&gt; SEQ ID NO 33

&lt;211&gt; LENGTH: 70

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 33

gggagaccac aacggtttcc ctctatctcc tgtgtcact ctcttctgtc aagaaggaga 60

tataccaatg 70

&lt;210&gt; SEQ ID NO 34

&lt;211&gt; LENGTH: 754

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic Construct

&lt;400&gt; SEQUENCE: 34

gggagaccac aacgguuucc cucuauucc ugugcucacu cucuucuguc aagaaggaga 60

uauaccaaug gacaacaccg aggacgucau caaggaguuc augcaguuca aggugcgcau 120

-continued

---

ggagggcucc gugaacggcc acuacuucga gaucgagggc gagggcgagg gcaagccua	180
cgagggcacc cagaccgcca agcugcaggu gaccaagggc ggccccugc ccuucgccug	240
ggacaucug uccccccagu uccaguacgg cuccaaggcc uacgugaagc accccgccga	300
cauccccgac uacaugaagc uguccuuccc cgagggcuuc accugggagc gcuccaugaa	360
cuucgaggac ggcggcgugg uggaggugca gcaggacucc ucccugcagg acggcaccuu	420
caucuacaag gugaaguuca agggcgugaa cuccccgcc gacggccccg uaaugcagaa	480
gaagacugcc ggcugggagc ccuccaccga gaagcuguac cccaggagc gcgugcugaa	540
ggcgagauc ucccacgcc ugaagcugaa ggacggcgcc cacuacaccu gcgacucaa	600
gaccguguac aaggccaaga agcccugca gcugcccgcc aaccacuacg uggacucaa	660
gcuggacauc accaaccaca acgaggacua caccguggug gagcaguacg agcacgccga	720
ggccccccac uccggcuucc aguaguuaug aaua	754

<210> SEQ ID NO 35  
 <211> LENGTH: 20  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 35

ugacagaaga gagugagcac	20
-----------------------	----

<210> SEQ ID NO 36  
 <211> LENGTH: 780  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 36

gggagaccac aacgguuucc cucuagaaau aauuuuguuu aacuuuaaga aggagauaua	60
ccaauaggugc ucacucucuu cugucaggug agcaagggcg aggagcuguu caccggggug	120
gugcccaucc uggucgagcu ggacggcgac guaaacggcc acaaguucag cguguccggc	180
gagggcgagg gcgaugccac cuacggcaag cugaccuga aguucaucug caccaccggc	240
aagcugcccg ugcccuggcc caccucugug accaccuga ccuacggcgu gcagugcuuc	300
agccgcuacc ccgaccacau gaagcagcac gacuucuua aguccgcca gcccgaaggc	360
uacguccagg agcgcaccau cuucuuaag gacgacggca acuacaagac ccgcccggag	420
gugaaguucg agggcgacac ccuggugaac cgcaucgagc ugaagggcau cgacuuaag	480
gaggacggca acauccuggg gcacaagcug gaguacaacu acaacagcca caacgucuau	540
aucauggccg acaagcagaa gaacggcauc aaggugaacu ucaagaucg ccacaacauc	600
gaggacggca gcgucgagcu cgccgaccac uaccagcaga acacccccau cgccgacggc	660
cccugcugc ugcccgacaa ccacuaccug agcaccagc cgcgccugag caaagacccc	720
aacgagaagc gcgauacau gguccugcug gaguucguga ccgcccggc guaaugaaua	780

<210> SEQ ID NO 37  
 <211> LENGTH: 20  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 37

-continued

---

gugcucacuc ucuucuguca 20

<210> SEQ ID NO 38  
 <211> LENGTH: 780  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 38

gggagaccac aacgguuucc cucuagaaau aauuuuguuu aacuuuaaga aggagauaua 60  
 ccaaugugca cgugcccugc uucccagug agcaagggcg aggagcuguu caccggggug 120  
 gugcccaucc uggugcagcu ggacggcgac guaaacggcc acaaguucag cguguccggc 180  
 gagggcgagg gcgauccac cuacggcaag cugaccuga aguucaucug caccaccggc 240  
 aagcugcccg ugcccuggcc caccucugug accaccuga ccuacggcgu gcagugcuuc 300  
 agccgcuaac ccgaccacau gaagcagcac gacuuuuca aguccgccau gccggaaggc 360  
 uacguccagg agcgaccacu cuuuucaag gacgacggca acuacaagac ccgcgccgag 420  
 gugaaguucg agggcgacac ccuggugaac cgcaucgagc ugaagggcau cgacuucaag 480  
 gaggacggca acauccuggg gcacaagcug gaguacaacu acaacagcca caacgucuau 540  
 aucauggccg acaagcagaa gaacggcauc aaggugaacu ucaagaucgg ccacaacauc 600  
 gaggacggca gcgugcagcu cgccgaccac uaccagcaga acaccccacu cgccgacggc 660  
 cccgugcugc ugcccgacaa ccacuaccug agcaccagc cgcuccugag caaagacccc 720  
 aacgagaagc gcgauacacu gguccugcug gaguucguga ccgcccggg guaaugaaua 780

<210> SEQ ID NO 39  
 <211> LENGTH: 21  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 39

ugcacgugcc cugcuucucc a 21

<210> SEQ ID NO 40  
 <211> LENGTH: 56  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 40

aaggagatat accaatggtg ctcactctct tctgtcaggt gagcaagggc gaggag 56

<210> SEQ ID NO 41  
 <211> LENGTH: 56  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 41

aaggagatat accaatgtgc acgtgcccctg cttctccagt gagcaagggc gaggag 56

<210> SEQ ID NO 42  
 <211> LENGTH: 771  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:

-continued

---

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 42

gggagaccac aacgguuucc cucuagaaau aauuuuguuu aacuuuaaga aggagauua	60
ccaauggugc ucacucucu cugucaggac aacaccgagg acgucauca ggaguucaug	120
caguucaagg ugcgcaugga gggcuccgug aacggccacu acuucgagau cgaggcgag	180
ggcgagggca agcccuacga gggcaccag accgccaagc ugcaggugac caagggcggc	240
ccccgcccc ucgccuggga cauccugucc cccaguuucc aguacggcuc caagggcuac	300
gugaagcacc cgcggacau ccccgacuac augaagcugu ccuucccgga gggcuucacc	360
ugggagcgcu ccaugaacuu cgaggacggc ggcguggugg aggugcagca ggacuccucc	420
cugcaggacg gcaccuucau cuacaaggug aaguucaagg gcgugaacuu ccccgccgac	480
ggccccguaa ugcagaagaa gacugccggc ugggagcccu ccaccgagaa gcuguacccc	540
caggacggcg ugcugaaggg cgagauucc caccgccuga agcugaagga cggcgccac	600
uacaccugcg acuucaagac cguguacaag gccaaagaag ccgugcagcu gcccgcaac	660
cacuacgugg acuccaagcu ggacaucacc aaccacaacg aggacuacac cgugguggag	720
caguacgagc acgcccaggc ccgccacucc ggcucccagu aguaaугааu a	771

<210> SEQ ID NO 43

<211> LENGTH: 771

<212> TYPE: RNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 43

gggagaccac aacgguuucc cucuagaaau aauuuuguuu aacuuuaaga aggagauua	60
ccaaugugca cgugccucg uucccagac aacaccgagg acgucauca ggaguucaug	120
caguucaagg ugcgcaugga gggcuccgug aacggccacu acuucgagau cgaggcgag	180
ggcgagggca agcccuacga gggcaccag accgccaagc ugcaggugac caagggcggc	240
ccccgcccc ucgccuggga cauccugucc cccaguuucc aguacggcuc caagggcuac	300
gugaagcacc cgcggacau ccccgacuac augaagcugu ccuucccgga gggcuucacc	360
ugggagcgcu ccaugaacuu cgaggacggc ggcguggugg aggugcagca ggacuccucc	420
cugcaggacg gcaccuucau cuacaaggug aaguucaagg gcgugaacuu ccccgccgac	480
ggccccguaa ugcagaagaa gacugccggc ugggagcccu ccaccgagaa gcuguacccc	540
caggacggcg ugcugaaggg cgagauucc caccgccuga agcugaagga cggcgccac	600
uacaccugcg acuucaagac cguguacaag gccaaagaag ccgugcagcu gcccgcaac	660
cacuacgugg acuccaagcu ggacaucacc aaccacaacg aggacuacac cgugguggag	720
caguacgagc acgcccaggc ccgccacucc ggcucccagu aguaaугааu a	771

<210> SEQ ID NO 44

<211> LENGTH: 21

<212> TYPE: RNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 44

uuuggauuga agggagcucu a	21
-------------------------	----

<210> SEQ ID NO 45

-continued

---

<211> LENGTH: 21  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct  
  
 <400> SEQUENCE: 45  
  
 uagagcucc uucaauccaa a 21

<210> SEQ ID NO 46  
 <211> LENGTH: 796  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct  
  
 <400> SEQUENCE: 46  
  
 gggagaccac aacgguuucc cuuagagcuc ccucaaaucc aaauaucucc uuagagcucc 60  
 cuucaaaucc aaagaaggag auauaccaau ggaaggaggc ucugugagca agggcgagga 120  
 gcuguucacc gggguggugc ccauccuggu cgagcuggac ggcgacguaa acggccacaa 180  
 guucagcgug uccggcgagg gcgaggcgga ugccaccuac ggcaagcuga ccugaaguu 240  
 caucugcacc accggcaagc ugcccugucc cuggcccacc cucgugacca ccugaccua 300  
 cggcgugcag ugcuucagcc gcuaccccga ccacaugaag cagcacgacu ucuucaaguc 360  
 cgccaugccc gaaggcuacg uccaggagcg caccaucuuu uucaaggacg acggcaacua 420  
 caagaccgcg gccgagguga aguucgaggg cgacaccug gugaaccgca ucgagcugaa 480  
 gggcaucgac uucaaggagg acggcaacau ccuggggcac aagcuggagu acaacuacaa 540  
 cagccacaac gucuauauca uggccgacaa gcagaagaac ggcaucaagg ugaacuuaa 600  
 gauccgccac aacaucgagg acggcagcgu gcagcucgcc gaccacuacc agcagaacac 660  
 ccccaucgcc gacggccccg ucgucgugcc cgacaaccac uaccugagca cccaguccgc 720  
 ccugagcaaa gaccccacg agaagcgcgga ucacaugguc cugcuggagu ucgugaccgc 780  
 cgccggguua ugaaua 796

<210> SEQ ID NO 47  
 <211> LENGTH: 24  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct  
  
 <400> SEQUENCE: 47  
  
 aucgaaguuc caaguccucu ucaa 24

<210> SEQ ID NO 48  
 <211> LENGTH: 805  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct  
  
 <400> SEQUENCE: 48  
  
 gggagaccac aacgguuucc cuaucgaagu uccaaguucc cuucaaauuc uccuaucgaa 60  
 guuccaaguc cucuucaaag aaggagauau accaauggac uuggaacuuc gagugagcaa 120  
 gggcgaggag cuguucaccg ggguggugcc cauccugguc gagcuggacg ggcgacguaaa 180  
 cggccacaag uucagcgugu ccggcgaggg cgagggcgau gccaccuacg gcaagcugac 240  
 ccugaaguuc aucugcacca ccggcaagcu gcccgugccc uggcccaccc ucgugaccac 300

-continued

---

```

ccugaccuac ggcgugcagu gcuucagccg cuaccgccgac cacaugaagc agcacgacuu 360
cuucaagucc gccaugcccg aaggcuacgu ccaggagcgc accaucuucu ucaaggacga 420
cggcaacuac aagaccgccg ccgaggugaa guucgagggc gacaccuccg ugaaccgcau 480
cgagcugaag ggcaucgacu ucaaggagga cggcaacauc cuggggcaca agcuggagua 540
caacuacaac agccacaacg ucuauaucu ggccgacaag cagaagaacg gcaucaaggu 600
gaacuucaag auccgccaca acaucgagga cggcagcgug cagcucgccg accacuacca 660
gcagaacacc cccaucgccg acggccccgu gcugcugccc gacaaccacu accugagcac 720
ccaguccgcc cugagcaaag accccaacga gaagcgcgau cacauggucc ugcuggaguu 780
cgugaccgcc gccggguau gaaua 805

```

```

<210> SEQ ID NO 49
<211> LENGTH: 77
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 49

```

```

gggagaccac aacgguuucc cucuauucc uugcaogugc ccugcuucuc caagaaggag 60
auauaccaau ggugagc 77

```

```

<210> SEQ ID NO 50
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 50

```

```

agaaggagau auaccaaugg ugcucacucu cuucugucag gugagc 46

```

```

<210> SEQ ID NO 51
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 51

```

```

Val Leu Thr Leu Phe Cys Glu
1 5

```

```

<210> SEQ ID NO 52
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 52

```

```

agaaggagau auaccaaugu gcacgugccc ugcuuucca gugagc 46

```

```

<210> SEQ ID NO 53
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

```

<400> SEQUENCE: 53

```

```

Cys Thr Cys Pro Ala Ser Pro

```

-continued

---

1                    5

<210> SEQ ID NO 54  
 <211> LENGTH: 52  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 54

agaaggagau auaccaaugg ugcucacucu cuucugucag gacaacaccg ag                    52

<210> SEQ ID NO 55  
 <211> LENGTH: 52  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 55

agaaggagau auaccaaugu gcacgugccc ugcucucca gacaacaccg ag                    52

<210> SEQ ID NO 56  
 <211> LENGTH: 109  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 56

gggagaccac aacgguuucc cuuagagcuc ccuuccaauc aaauaucucc uuagagcucc                    60

cuuccaaucca aaagaaggag auauaccaau ggaagggagc ucugugagc                    109

<210> SEQ ID NO 57  
 <211> LENGTH: 4  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 57

Glu Gly Ser Ser  
 1

<210> SEQ ID NO 58  
 <211> LENGTH: 118  
 <212> TYPE: RNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 58

gggagaccac aacgguuucc cuaucgaagu uccaaguuccu cuuccaaaucc uccuaucgaa                    60

guuccaaguc cucuuccaaag aaggagauau accaauggac uuggaacuuc gagugagc                    118

<210> SEQ ID NO 59  
 <211> LENGTH: 5  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 59

Asp Leu Glu Leu Arg  
 1                    5

---

The invention claimed is:

1. An mRNA comprising a microRNA-binding site located 5' to the ribosome-binding site and a nucleotide sequence located 5' to the microRNA-binding site, the nucleotide sequence being complementary to the ribosome-binding site. 5

2. The mRNA according to claim 1, wherein the microRNA-binding site has a sequence complementary to a microRNA selected from miR164, miR170, miR171, miR156, miR159a or miR163.

3. A liposome comprising an mRNA according to claim 1 10 encapsulated therein.

4. The liposome according to claim 3, wherein the liposome is produced by a method comprising steps of:

mixing one or more phospholipids, the mRNA, a cell-free translation system, and an aqueous solution into an oily liquid to form a W/O emulsion in which the mRNA and the cell-free translational system are encapsulated in the phospholipid vesicle; 15

adding an oily liquid containing outer membrane lipids dissolved therein, to an aqueous phase to form a molecular membrane in which the lipids are arranged at the oil/water interface; and 20

adding the W/O emulsion to the oil phase side of the interface and moving the W/O emulsion to the aqueous phase side of the interface such that the outer membrane lipid is added outside of the W/O emulsion to form a liposome. 25

5. A translation/expression regulation system comprising an mRNA according to claim 1.

6. The translation/expression regulation system according to claim 5, further comprising a microRNA complementary to the microRNA-binding site. 30

\* \* \* \* \*